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Abstract
Drug delivery is the most important factor of many therapies, but a lack of technology and
research have led to a very generalized understanding of drug kinetics. Insulin pump therapy for
the treatment of Type 1 Diabetes depends on precise delivery of the hormone into the adipose
region between the dermis and underlying muscle. The kinetics of insulin within the adipose tissue
environment is not well understood and varies greatly case to case. The use of computation fluid
dynamics (CFD) models to study insulin kinetics in relation to influential factors will lead to a
better understanding of the characteristics of insulin infusion.
Previously published studies revealed a single study using CFD to analyze insulin delivery,
which indicated CFD research of insulin delivery was viable, but also needed more development
for a complete biological computational model to simulate insulin delivery. Other studies have
presented research in many of the key areas needed to create such a CFD model incorporating
interstitial adipose tissue fluid flow and insulin delivery. Important characteristics were able to be
identified from published research aiding in the development of an adipose tissue CFD model.
A porous media CFD model simulating the interstitial flow within adipose tissue was
developed and modified to include insulin infusion in the model. The insulin deposition modeling
was verified through the agreement with published study results. A study to analyze the effect of
infusion set design and adipose tissue thickness on insulin deposition and dispersion was
developed. This study considered the five most common cannula geometries currently on the
market as well as adipose tissue thicknesses found across the body mass index range of patients,
resulting in the parametric analysis of twenty-five cases.
Through the use of both graphic and statistical analysis, the results of the study indicated
that both the cannula design and adipose tissue thickness have a significant effect on deposition
and dispersion of insulin. Further, there was a clear difference between the thin adipose tissue and
thick adipose tissue insulin deposition and dispersion observed. It was also found that as the lower
angle cannulas decreased the dispersion of insulin within the tissue, but the cannula length at these
infusion angles did not significantly impact the deposition and dispersion of insulin. In conjunction
with previous understanding of insulin kinetics, the results indicated using a similar cannula
geometry in lean and thick adipose tissue would result in largely different drug absorption
characteristics. Further there would likely be a large variation in the insulin kinetics even within a
singular patient due to adipose tissue thickness deviation.
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Therefore, further research in the area of insulin kinetics with relation to the cannula design
and tissue thickness is highly warranted, especially with autonomous insulin pumps already on the
market. The best way to further improve insulin treatment would be to achieve a more precise
delivery and absorption across each adipose environment within a singular patient’s anatomy. This
study proved the use of computational models such as CFD is a very useful technology for such
research in insulin delivery, but additional studies are required to further utilize computational
models to enhance the understanding of insulin delivery kinetics within adipose tissue and the
different factors effecting it.
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1. Introduction
Type I Diabetes treatment advancements have been one of the greatest developments of
managing autoimmune conditions in the past several decades. This has come through the
successful synthesis of a human insulin analog, the introduction of continuous pump infusion, and
even the use of constant glucose monitor technology to give continuous glucose updates leading
to almost completely autonomous pump control. The more treatment methods develop, the greater
the trend toward individualized management on a patient-by-patient basis. For this step to
completely take place though, it requires the ability to understand and predict the influence of
factors on a patient’s insulin uptake and dispersion. There has been no readily available way to
easily measure and simulate the anatomical conditions found in the subcutaneous adipose region
where the insulin is infused but utilizing tools such as computational fluid dynamics (CFD) and
individualize tissue models could lead to a better understanding of the flow and kinetics of the
drug within the biological tissue. The use of patient models could better help determine
management decisions for each individual such as which infusion set, insulin, and delivery rate
would be best suited for their condition treatment.
1.1 Background
The human body has a complex network of systems which are responsible to control
various functions or maintain life sustaining levels of molecules throughout the body. One of these
important molecule levels to be maintained is the amount of glucose in the blood. The homeostatic
balance of blood glucose is maintained through the release of either glucagon or insulin by the
pancreas to prevent hyper or hypoglycemia based on the current blood glucose concentration as
shown in Figure 1. Diabetes is a disease which disrupts this cycle of blood glucose control,
resulting in the inability to maintain a healthy homeostatic blood glucose. The homeostatic system
can be interrupted in two major ways, which create the classifications of Type I and Type II
Diabetes.
Type II Diabetes is associated with a resistance to insulin, typically related to several
factors including the individual patient’s genetic, body mass index, and daily dietary and exercise
routine. The condition can often be managed by lifestyle changes as well as supplementary drugs
to change metabolism, boost insulin sensitivity, or give a small amount of supplemental insulin.
In very severe cases, full time insulin therapy may be required.

18

Type I Diabetes on the other hand is a completely autoimmune condition where the beta
cells of the pancreas that produce insulin are completely destroyed by the patient’s own immune
response. Little is known about why this happens or what triggers it, and the onset can be soon
after birth or even into one’s mid to late 20s. Therefore, the only treatment for a Type 1 Diabetic
to maintain a healthy blood glucose level is by frequent insulin bolusing, whether through shots or
continuous infusion. This insulin therapy requires constant blood glucose monitoring and insulin
adjustment for conditions such as eating, activity, sickness, and many other daily factors that in
healthy individuals would be regulated by pancreatic insulin production. These insulin boluses are
delivered into the subcutaneous fatty tissue, called adipose tissue.

Figure 1. Homeostatic cycle of blood glucose control.
1.2 Adipose Tissue
The adipose tissue into which insulin is injected is a special connective tissue composed of
white adipocytes suspended in a fibrous collagen network [1, 2, 3]. The adipocyte function to store
19

excess energy from carbohydrate consumption in the form of triglycerides [1]. This fatty tissue is
found between the dermis and muscles layers, as shown in Figure 2.

Figure 2. Adipose tissue and subcutaneous bolus into the region.
A more in depth look at the adipose tissue anatomy depicts the tissue not only contains the
fatty adipocytes, but also there are blood capillaries and lymphatic capillaries flowing through the
tissue as well. Each of the adipocytes is in contact with at least one capillary for the transfer of
nutrients for energy storage [1, 4, 5]. These capillaries are also responsible driving the flow of
interstitial fluid found in the space between adipose cells as the fluid is transferred through the
capillary walls into the extracellular space and then back into either the blood capillaries or
lymphatic capillaries driven by osmotic pressure gradients.
1.3 Subcutaneous Drug Delivery
A drug being injected into this subcutaneous tissue area fills the interstitial space around
the adipocytes, mixing with the interstitial fluid. Figure 2 illustrates an example of a bolus of
insulin in this adipose area of tissue looks like between the dermis and muscle. Once the drug is in
in the space it is either absorbed into the blood capillaries, putting the drug directly into the blood
stream, or it is absorbed through the lymphatic capillaries becoming part of the lymphatic fluid
filtered in the lymph nodes before being added back into the blood stream. The path the drug takes
depends on the drug type and molecule size, but also may depend on the delivery location and
interstitial flow once the drug is in the tissue [2].
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Interstitial drug delivery has posed many potential benefits, the first of which is the various
areas available on the body appropriate for administration. As shown in Figure 3, there are large
deposits of adipose tissue around the body including the upper arms in the area between the biceps,
triceps, and shoulder, the abdominal region, the upper back, the thighs, and the upper buttocks/hip
region, as well as the calf region being proposed for viable drug delivery [6, 7]. Also, since
injection sites are not directly into the blood stream or quickly absorbing muscular tissue, the risk
for systematic infection is much lower in a subcutaneous drug delivery system than in an
intravenous or intramuscular system [8]. The diffusion and absorption dynamics of drugs injected
into the adipose region could also be conducive for a more biologic method of supplementing or
replacing secreted hormones such as insulin. These benefits of subcutaneous drug delivery make
it a very viable solution for self-administered treatments and condition management.

Figure 3. Suitable subcutaneous drug injection areas of body.
Subcutaneous drug delivery does have its limitations though, including a limited volume
of infusion, degradation of therapeutic and injection site over time, localized reactions, and
variability in inter-individual doses across adipose tissue deposits [8, 9, 10]. Many of these
limitations are associated with single point injection administration though, which has been shown
to limit the volume of drug able to be administered and mechanical dispersion characteristics of
the drug in the adipose tissue, especially when considering large molecules [2, 8]. Also, the
conditions affecting the dynamics of drug absorption are not clearly understood in human patients
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by current research due to complexity of the tissue region, leading to more variability in drug
therapy than is desired in a single patient’s treatment [12, 13, 14]. Even given the current
weaknesses of subcutaneous drug delivery systems though, there are many applications for
subcutaneous injections throughout therapeutics, including immunoglobulins immunodeficiency
treatment, hydration, and nutrition supplementations, Treprostinil hypertension treatment, pain
killers, and the cancer drug trastuzumab, which are proven as viable for subcutaneous delivery [3,
15, 16, 17]. The most large-scale use of subcutaneous delivery in the medical field currently though
would be the 1.15 million Type 1 Diabetics in the United States alone that depend daily on selfadministered subcutaneous injections or infusions of insulin to sustain glycemic homeostasis [18].
1.4 Continuous Insulin Infusion
Continuous insulin infusion, which is more commonly known as pump therapy, has been
gaining momentum as the best method for insulin delivery in the majority of patients over the
past several decades. Pump therapy replaced injections of insulin using manual syringes with an
automated pump to deliver the insulin, and a cannula placed in the subcutaneous tissue as the
means of delivery rather than a small gauge hypodermic needle. A pump system compared to the
typically used pen syringe and needle system used to deliver insulin are shown in Figure 4
below.

(b)
(a)
Figure 4. (a) Insulin pump system versus (b) injection pen and hypodermic needle.
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Using pump therapy allows for small amounts of insulin to be continuously administered
throughout the day, where manual injections required more injections and even different types of
insulin to maintain a consistent basal level of insulin in the patient for the best glycemic control.
A pump system often fits better into patient’s lifestyle, as it requires less intensive injection site
management (the cannula only needs to be changed every 2 to 3 days). Further, newer systems
have incorporated constant glucose monitoring (CGM) technology to better help insulin decisions
or allow for fully autonomous basal insulin control based on the interstitial glucose concentration
and trends returned by the sensor. Studies have indicated that the use of pump therapy has been
rapidly increasing in Type 1 Diabetic patients, with a 52% increase in use from 1995 to 2017, from
1% up to 53% respectively [19]. This drastic increase would be expected to continue to grow as
CGM, and therefore autonomous insulin delivery, continue to improve over the next several years.
One of the key components in the pump system is the infusion set that contains the cannula,
which is directly responsible for accurate and consistent insulin delivery into the adipose tissue.
The interface between the cannula and adipose tissue is responsible for the successful delivery of
the insulin to the body, which depends on the dispersion within the tissue over time as well.
Currently there are 4 major design types of the infusion sets with a multitude of minor variations
such as cannula length or material between each pump manufacturer. These major designs include
a 90-degree cannula angle, 45-degree cannula angle, a 30-degree cannula angle, and a “flexible”
cannula angle (designed to be inserted at very low angles in subcutaneous tissue). Even though
these variations are present, the majority of the infusion set for international distribution are
actually manufactured in one factory in Denmark [8]. The major designs also have not significantly
changed since the introduction of early insulin pumps onto the market in the late 1980s.
1.5 Current Evaluation Systems of Infusion Sets
Evaluation of infusion sets for use in insulin pump therapy is completed in two ways, one
by the manufacturers, and one by the patients and their doctors. The evaluation completed by the
manufacturers of the infusion sets is required by the drug administration agencies around the world
to prove the system as a whole is fit for use in insulin delivery. These evaluations are required to
prove the system in fact does deliver insulin accurately and does not provide an added danger the
patient’s health, but the exact regulations about this vary from agency to agency around the world.
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The second evaluation is very patient dependent, as it is the determining of which infusion
set on the market is in fact the best for their own use. This process is currently very subjective, and
often comes down to trial and error, comfort, and in the end preference. This has resulted in varying
trends of which infusion set designs are used in the different international areas [8, 20]. Often,
there is input from an Endocrinologist in the infusion set decision, but it still relies heavily on
experience, availability, and preference, with little to no ability to predict how the given infusion
set would in fact work to deliver the insulin to each given patient based on their body condition.
Through the use of CFD modeling to create a simulated adipose tissue environment and prediction
of the insulin deposition and dispersion, a greater understanding of insulin kinetics could be
achieved. This understanding could lead to applications to current infusion of insulin as well as a
step in the direction of individualized patient care based off their own body parameters.
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2. Literature Review
CFD has just begun to break into the medical field in the past decade, and therefore only
one significant study into the simulation of insulin delivery by pump therapy using CFD was able
to be located. The literature review was able to indicate the various components that would be
required to make an accurate CFD model of adipose tissue fluid flow for the basis of studying
insulin kinetics though by analysis of similar CFD studies considering flow in other tissues, known
mechanics of drug and insulin dispersion in tissue, as well as characteristics unique to adipose
tissue.
2.1 Subcutaneous Therapeutics Delivery
The subcutaneous region is a complex and variable region of tissue, which has diverse
characteristics depending on the area of the body and the patient. The development of models and
simulations of drug dynamics in the tissue is difficult due to these individualized and unique
characteristics of the tissue. Animal simulation have even been shown to produce very different
results from human tissue, as the vascular uptake and biodistribution often happens at very
different rates between species [21]. There are many factors contributing to these varied results in
drug distribution and absorption after administration, including but not limited to peptides and
enzymes present, species, temperature, aggregation at injection site, etc., as shown by a
summarization of the factors within a subcutaneous drug delivery system in Figure 5. The impact
of many of these factors on drug absorption has not been clearly quantified in humans though,
resulting in the varied results observed in drug administration. These varied results are attributed
to factors such as molecule size, injection rate, age and sex, and foreign body reaction in the human
physiology associated with subcutaneous drug delivery as currently understood through research
[3, 16, 21, 22].
The first factor in a subcutaneous drug delivery system to influence the biotherapeutics of
drug diffusion and absorption in the tissue is the size of the injected molecule. As shown in Figure
5, the size of the molecule delivered determines the route in which the drug is transported
systemically to the body. Smaller water-soluble molecules from <1 kDa and even reportedly up to
<20 kDa can be directly absorbed into the capillaries running through the tissue by the oncotic
pressure gradients [2, 16, 21]. The drug can be completely absorbed in several hours, or even
minutes, based on its size, the capillary flow in the tissue, and the oncotic pressure gradients.
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In the case of larger molecules though, in the range of >20 kDa, the method of absorption
would be through the bulk fluid flow in the lymphatic capillary system [2, 16, 21, 23]. This is a
much slower route of delivery, as lymphatic flow is about 0.2-2% the rate of blood, indicating drug
absorption and systemic delivery can take days or weeks to reach peak levels [16, 21]. Therefore,
by the characteristic differences in the routes of absorption based on molecule size, it can be noted
the absorption rate of the drug is often directly proportional to size. This can play an important
role in the desired rate of absorption, as using the same adipose tissue can be used to optimize both
slow and fast absorbed drugs based primarily only on designing the molecule to fit the size
specification matching the absorption rate desired.

Figure 5. Factors influencing drug delivery through a subcutaneous delivery system.
Insulin specifically can be delivered as a monomer, dimer, and hexamer with respective
molecular weights of 6 kDa, 12 kDa, and 36 kDa [24]. The insulin monomers and dimers are
absorbed into the blood capillaries due to their size, but the hexamers are reliant on the lymphatic
system for absorption due to being larger than 20 kDa [24]. These two paths of absorption are
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what separate “rapid-acting” from “slow-acting” insulin, as lymphatic absorption results in a
longer delay before the drug reaches the blood stream [2, 16, 21, 23, 24].
The injection rate of the drug can have significant impact on the drug dispersion into the
adipose tissue and the absorption into the capillary or lymphatic system, and therefore play a
critical role in the mechanics of the drug delivery. Drug solution transportation through a tissue
has been modeled as a fluid flowing through a porous medium, and therefore have been assumed
to follow the Navier-Stokes equation in correlation to subcutaneous drug injection/infusion [16].
Injection rate research has also shown that the depth of permeation of the drug into the
tissue can be inversely related to the rate of drug injection. A faster rate of delivery results in a
more planar spread of diffusion parallel to the surface of the tissue, while a slow drug injection
rate results in a deeper permeation into the subcutaneous tissue with the drug [16]. This
understanding could pose great importance for subcutaneous drug delivery systems, as depending
on the composition of the tissue across the anatomical areas used for delivery, the injection rate
can help to target areas with a high concentration of vascular capillaries or lymphatic capillaries,
especially in connection to the size molecule being delivered.
Different infusion rates could be utilized for the different injection/infusion viable regions
based on the physical tissue properties in order to yield consistent drug metabolism across each
site on the patient. For example, in a patient’s abdominal subcutaneous tissue, differences in
capillary and lymphatic capillary concentrations have been noted from proximal regions on the
body to distal regions on the body [21]. Using CFD to simulate different combinations of local
tissue characteristics, infusion set designs, and injection rates could lead to a better patient
dependent insulin delivery, and even consistent delivery across the different anatomical regions
used to deliver the drug.
2.2 Insulin Specific Drug Delivery
In addition to an understanding about drug absorption from the anatomical function of the
adipose tissue region, there has been studies completed to quantify the ex vivo mechanics of insulin
delivery into adipose tissue. One of these such studies was considering insulin injection pens, and
the relationship of the interstitial pressure related to delivering insulin. This was of importance to
understand how delivery devices such as insulin pens and pumps need to overcome the force create
by the delivery of insulin into the tissue that already is saturated with interstitial fluid [25]. In the
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case of the injection delivery, which has a typical delivery rate of 100 μl/s, the delivery flow rate
into the tissue was found to significantly decrease when the insulin was delivery into the tissue
and a counter pressure was developed while it the drug took time to disperse into the porous
medium and interstitial fluid [25]. Through this, a model of the permeability of the adipose tissue
region was able to be developed based upon the insulin injection delivery which was found to be
in the range of (8.9 ± 4.7) ´ 10-11 m2 [25].
Another study was completed to study the development of the insulin depot immediately
after an insulin bolus using by insulin pump and 90° x 8 mm long infusion set cannula. This
research was completed in order the better understand the dynamics of the insulin with the
subcutaneous adipose region during delivery. The insulin was dyed with food colorant then
delivery into porcine tissue that was 15 min postmortem at an infusion rate of 120μL/min for a
150 μL bolus. The samples were then flash frozen to preserve the insulin depot formation. The
depot of each sample was then digitally reconstructed by imaging the stain tissue area every 100
μm into the tissue [26]. Analysis of the samples showed the insulin was distributed in channels
between the adipocytes of the tissue, with no adverse effects on the cells. The deposition pattern
observed was a very branched structure and was quite variable from sample to sample [26].
Massaging the sample during infusion was shown to have increased the insulin distribution
distance, but the overall observed reconstructions of the deposits showed very little patterns in
their appearance [26].
The study infusing insulin through a pump did show one general observation about insulin
delivery to adipose tissue, which was that the insulin did not deposit in a round pattern around the
end of the cannula. It instead created an elliptical depot, that had the largest outreach from the
cannula at the plane in line with the end of the cannula. Therefore, it was concluded the previous
assumption that insulin deposition was spherical about the cannula tip did not fit the actual
kinematic deposition of the insulin delivered to the tissue [26]. The study also proposed that the
formation of the channels through which the insulin flowed, which were observed between the
adipocytes, depends directly on the mechanical properties of the collogen matrix supporting the
adipocytes in the adipose region. The overall force driving distribution of the insulin was
concluded to be the related to the hydraulic flow and resistance for lateral spreading compared to
fluid resistance to pass through to another collogen layer [26].
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2.3 Interstitial Fluid Flow in Tissue
Flow of fluid through tissue could be called the highway of transportation in the body.
Fluid dynamics in the body governs how different molecules are able to be transported around the
body to the areas and cells that require them. To this extent, there are various body fluid
compartments found throughout the body, each containing various concentrations of the water
found in the body. Adipose tissue contains a low water content at only 10% to 20% compared to
skin and muscle which have a water content of 70% to 80% [27]. No matter the water content
though, this fluid is continually flowing through the extracellular space in the tissue, driven by the
osmotic interface between the capillary fluid and interstitial fluid in the tissue [27, 28]. Fluid
dynamics within tissue have been shown to play an important role in physiological functions in
the body, especially tissue that the vascular density has been documented to be low such as
ligaments and tendons [28-32]. Although in vivo and ex vivo experiments have documented that
this interstitial fluid flow can be vital for certain biologic functions and mass transport, there are
few in vivo direct measurements of interstitial fluid flow characteristics, especially relating to
adipose tissue fluid flow [33, 34]. It has been documented though that flow velocities on the order
of 0.1-2.0 μm/s are found in tissue, with velocities reaching even up to 4.0 μm/s [35].
2.4 CFD in Interstitial Fluid Flow and Drug Delivery
It was found that CFD models have found uses in various biological and medical scenarios
over the past decade in order to better understand biological processes or drug administration,
especially in the areas of cerebral spinal fluid flow, tumor drug delivery, and studying interstitial
fluid flow in tendons and ligaments [33, 35-40].
It has been presented that the development of computational models could be used to
understand spinal flow, as well as overcome drug delivery barriers that currently hinder therapeutic
agents for chronic and degenerative diseases [36]. Using a CFD model coupled with diffusiontensor imaging, an advanced 3D fluid transport model of the spinal region was able to be presented
and validated by prior in vivo experimentation [36]. It can be noted that diffusion-tensor imaging
is a non-invasive technology used to track the water diffusion along white matter tracts in the brain
[36]. In another study, a CFD model was developed to further understanding of the
pharmacokinetics of the regenerative molecular therapy anti-Nogo-A for spinal cord injuries [37].
It was discovered that while the assumption that biological factors such as breathing and cardiac
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cycles are the primary driving effect on the drug distribution were valid, the drug injection velocity,
injection needle orientation, and bolus amount also did have an effect on the drug distribution
pattern in the spinal canal [37]. This gave insight into the challenges of drug delivery targeting
using the cerebral spinal fluid as a delivery mechanism.
Similar to looking at drug kinetics being delivered in the spinal region, CFD has also been
used in analyzing drug kinetics around tumors. Drug delivery to tumor tissue is highly influences
by both therapy and biological factors, which has limited therapeutic methods. Porous media CFD
models have opened the door to better understand the factors affecting penetration depth of
therapeutic drugs into the tumor, and therefore provide the basis to attempt the optimization of
drug delivery for tumor penetration [38]. A more recent study has looked at the fluid flow between
the healthy tissue around a diseased region in relation to drug uptake as well. Using a combination
of a CFD model and in vivo imaging, a prediction of heterogenous uptake and spatial distribution
of therapeutics was able to be made [38]. The study was even able to predict the effect of on the
vascular structure of a tumor by the uptake of a vascular disrupting agent [38]. Further, a study
found that the permeability of nanoparticle to diffuse into a tumor was highly dependent on the
pressure gradients within a tumor using a CFD model driven by oncotic pressure [39].
While the previous studies discussed were able to indicate a viability for use of porous
media CFD models to be used in studying drug delivery and dispersion, subcutaneous tissue fluid
flow modeling presents its own unique challenges, as it is a tissue region whose fluid mechanics
is driven by the fluid exchange between the interstitial region and the capillaries running through
the tissue. There have however been several studies completed to compare different computational
modeling theories as well as parameters affecting interstitial fluid flow. The three mathematical
models used to describe interstitial flow in the fibrous matrix are the Stokes, Brinkman, and Darcy
equations [40-45].
It can be noted that the Stokes equation was built upon the assumption of incompressible
flow, where the Navier-Stokes equation can be applied based on flow velocities. Since very low
Reynolds numbers are characteristic of the interstitial flow, the inertial term of the Navier-Stokes
equation can be described as negligible compared to the viscous term. Therefore, all that remains
would be the Stokes equation [28, 42]. The Brickman and Darcy equations are instead based upon
the hydraulic permeability of the matrix of the porous media being considered. The Brickman
equation reduces to the Darcy equation when the permeability is small [28, 42]. It was found in
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this comparative study that major difference between the Stokes and Darcy models was the
velocity distribution in the cross-sectional area. Also, the Brinkman equation was similar to the
Stokes equation when the permeability was large (permeability > 1.0 x 10-8 m2), and an ample
approximation of the Darcy equation at lower permeabilities (permeability < 5.0 x 10-12 m2) [28].
A conclusion also made was that there was little effect on the interstitial flow when considering
the material as anisotropic versus isotropic [28].
Using these principles, work has been done to simulate interstitial fluid flow in both the
interosseous membrane as well as ligaments [28, 33, 41, 42]. These areas have capillaries that are
parallel to the length of tissue, causing the driving interstitial flow in the lengthwise direction of
the tissue based off the Starling relationship for fluid transmission between the capillaries and the
interstitial region based on hydrostatic and oncotic pressure [28, 33, 41, 42]. This has allowed for
the study of the interstitial velocities in these tissues as well as considering the stress on the wall
of an interstitial cell due to the interstitial flow [28, 33, 41, 42].
2.5 CFD in Insulin Delivery
There was a single published research study, a master’s thesis by Zedelmair in 2016, using
CFD to study the deposition and dispersion of insulin into subcutaneous tissue using pump therapy.
This study did create a CFD representation of adipose tissue to study insulin delivery, looking
especially at the drug deposition concentration patterns after delivery and several different cannula
designs the author created [46]. From this, the study was able to provide conclusions of how insulin
delivery looks in a 2D and 3D domain. The study also considered the use of differing porosities in
the primary axis domain directions to simulate the anisotropic nature of the depot development
noted in a prior ex vivo study that result in an elliptical insulin depot shape [26, 46]. The use of
this anisotropic porosity in the CFD model presented was found to accurately model the insulin
depot in accordance with the previous ex vivo research. Zedelmair was also able to indicate there
were noticeable difference in the size and shape drug deposit in the tissue after delivery between
cannula designs and insulin flow rates.
While this study was a CFD model of insulin delivery, there were a few things noted though
that were assumed or not included in the model, the largest of which was the assumption the
interstitial fluid was stagnant in the adipose tissue. As previously discussed, the interstitial fluid in
the adipose region is constantly moving, as it is essential for biologic function within the body.
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This fluid flow within the extracellular area of the adipose region would have an impact on the
insulin deposition and dispersion, especially over time.
In connection with this also, the 3D model domain described was a quarter cylinder, with
an outlet in one direction and a symmetry axis assumption about the axis of the cannula [46]. This
assumption would be valid considering stagnant interstitial fluid as the discussed study presented,
but not if the interstitial fluid would be considered as a flowing fluid in the 3-dimensional space
of the domain. Therefore, if interstitial adipose tissue fluid flow is being modeled with the insulin
delivery, the CFD model domain would not be able to consider the deposition area as symmetric
around the axis of the cannula as presented by Zedelmair.
Finally, the study did not consider the factors of currently available infusion set geometries
or adipose tissue thickness and their effect on insulin delivery. While the research did look at
several different cannula designs, these designs were created by the author, with no indication of
being models of currently marketed designs available to patients. Further, the study did not
consider the adipose region in various tissue thicknesses but assumed one thickness of 13.9 mm
for the duration of the research [46]. Therefore, while this previously published research did
present and use a CFD model to study insulin delivery, there were various factors of the research
that did not allow for application to be made to current patient therapy decisions.
2.6 Adipose Tissue Characteristics
Though several studies on interstitial fluid flow using CFD were able to be found, adipose
tissue has a number of special characteristics that make it unique compared to the dermis or muscle
tissue around it. Two of the main factors to consider are the adipose tissue thickness and
vascularization.
Adipose tissue has variable thickness throughout the body, as well as between individual
patients. It has been presented that the subcutaneous adipose tissue thickness has a direct effect on
insulin therapy and the chance for intramuscular delivery if the adipose region was penetrated
completely, thus making the adipose thickness one of the primary factors in needle and infusion
set selection [47]. Various studies have been performed looking at the adipose tissue thickness in
different control groups, even comparing different anatomical regions within the sets of individuals
[48-50]. The most notable results in the studies found was using a set of adults which ranged from
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lean to obese, with a body mass index (BMI) range of 18.6-40.3 kg/m2 [48]. The results presented
in this study are found in Table 1.
These results indicate a very large range of adipose tissue thicknesses can be present in one
patient as well as across the entire spectrum of body sizes, considering the range in the adipose
tissue thickness was found be from 5 mm all the way up to 30 mm in the regions presented as
suitable for insulin delivery in patients [48]. Considering tissue thickness has been mentioned as
one of the large contributing factors to insulin absorption, this range in adipose tissue thickness
could be a significant factor in insulin absorption and dispersion.
Table 1. Median observed adipose tissue thickness in lean and obese patients [47].
Anatomic

Lean Median

Obese Median

Location

Thickness (mm)

Thickness (mm)

Upper Abdomen

6

28

Lower Abdomen

10

31

Distal Triceps

5

6

Lateral Thigh

9

19

Frontal Thigh

5

8

Medial Calf

3

6

Another critical factor that sets adipose tissue apart from other anatomical regions would
be the vascularization of adipose tissue. The capillaries in other tissues studied for interstitial flow
have a patterned longitudinal capillary direction, but adipose tissue has a much more meandering
pattern throughout the tissue [4, 51, 52]. Also, it has been found that conditions such as obesity
lower the capillary density in the subcutaneous adipose tissue [53]. Therefore, the vascular and
lymphatic capillary density can largely vary from patient to patient as well in their respective
adipose tissue region.
Similarly, adipose tissue has a more uniform structure lending itself to produce a more
bidirectional interstitial fluid flow pattern compared to muscular or ligament tissue, which has
been shown to have very a longitudinal anisotropic interstitial fluid flow [5, 33, 41, 42, 54]. This
structure is due to the unique generation of adipocytes in the extracellular matrix in an organized
manner, grouping adipocytes into lobules, and forms a well-organized network for proper adipose
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tissue function [5, 54]. Adipose tissue has still been observed to have an anisotropic flow
component though, especially with respect to drug delivery. The extracellular matrix layers that
support the adipocyte network have been shown to buffer the vertical drug dispersion [3, 21, 26].
The exact mechanics of how these lower permeable extracellular matrix layers affect the
hydrodynamic forces and permeation within the tissue though is not well quantified, it has only
been observed as an influencing factor of drug deposition and dispersion in adipose tissue [3, 26].
A property of adipose tissue that has not been well documented is the tortuosity, which has
not been well quantified for any biologic tissue. Tortuosity is defined as the ratio between the
shortest distance a fluid particle takes to the shortest straight-line distance from the entry point to
the exit point of the domain [55, 56, 57, 58]. Therefore, this would indicate a particle taking a
straight path from one end of the domain to the other end of the domain would result in a tortuosity
of 1, and as the particle path deviates toward a more sinusoidal path, the tortuosity would increase.
If just considering a porous medium with a homogenous packing of uniform particle sizes, the
largest contributing factor to tortuosity would be the porosity [55]. There is little described about
adipose tissue in relation to its tortuosity, but tortuosity of tissue and bone has become of
importance in previous years. This is because tortuosity has become an important factor in
scaffolding design for tissue and bone reconstruction [55, 56, 57]. Similarly, tortuosity has been
studied in respect to the extracellular space around the brain, giving light to how tortuosity would
be affected by the porosity of the matrix as well as the type of matrix the domain is composed of.
It was found at low porosities, the tortuosity of both 2D and 3D models follow very closely with
the “narrow channel approximation” as well as the Maxwellian prediction, giving tortuosity values
decreasing from 1.23 to 1.12 in the porosity range of 0 to 0.5 [58]. For low porosity cases, the
tortuosity can be estimated by Equation 1:
"
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where λ is tortuosity and θ is a diffusion permeability. This diffusion permeability can be
approximated using the “narrow channel approximation”, which is shown below:
!
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(2)

where α is the volumetric porosity of the medium. These approximations have been shown to be
viable to predict the tortuosity of tissue with low permeability, whether it was a cube construct
with varying gap widths, loosely dispersed spheres, or random 3D geometry of convex polyhedral
[58].
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2.7 Summary of Research
Summarizing all the published studies found indicated there are a multitude of published
works in major component areas overlapping with using CFD techniques to study insulin delivery
into adipose tissue, but only one published work by Zedelmair considered using CFD to study
insulin delivery. Table 2 shows an overview of all these topics covered in the previously published
studies. It can be noted the critical topic columns for the current presented study are highlighted in
orange. It can be clearly observed that there was a clear divide between studies considering
subcutaneous drug delivery and its biologic components and those studies modeling biologic
tissues using porous media models and CFD techniques.
Many of the studies considering subcutaneous drug delivery and more importantly insulin
delivery in Type 1 Diabetics emphasize how important understanding the mechanics behind the
drug delivery and dispersion are to better manage condition treatment, but at this point in time
there has not been a clear link studied between the available infusion sets on the market and which
are most viable for drug delivery in different thickness tissues. The current evaluation method to
determine which infusion set works for an individual patient is vastly lacking and time consuming.
It could be greatly improved through the use of an accurate model to understand how each infusion
set delivers insulin in different adipose tissue conditions. This could help to improve effective drug
interaction in the body as well as improve overall homeostatic balance of blood sugars in Type 1
Diabetic patients no matter what anatomical area of adipose tissue is being used to infuse the
insulin.
Although the simulation of insulin delivery using CFD was studied by Zedelmair, various
parameters were not considered in the model, such as interstitial flow, varied adipose tissue
thickness, and the different cannula designs that are currently available on the market. Therefore,
based off the published research, an even more comprehensive model of adipose tissue to study
the effect of different available infusion sets and adipose tissue thicknesses on the delivery of
insulin in a patient could be developed based upon the research found. This model was able to be
used to further the understanding of current insulin delivery methods available to Type 1 Diabetics.
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Table 2. Research summary of previous studies published.
Citation

CFD
Analysis

CFD
Theory

Porous
Media

1
2
3
4
5
7
8
9
10
11
12
13
14
15
16
17
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
62
63
64
65
67
68
69
71
72
73
75
77
78
80
81

Mathematical
Modeling

Interstitial
Flow
X

X

Adipose
Tissue
X
X
X
X
X
X
X

Tissue
Structure
X
X
X

Tortuosity

Turbulence

Vascularization

X
X
X

X
X

X
X
X

X
X
X
X

X

X

X
X

X

X

X

X

X

X

X
X
X
X
X
X
X
X

X
X
X
X
X
X
X
X
X
X
X
X

X
X
X
X
X
X
X
X
X
X
X
X

X
X
X
X
X
X
X
X
X
X
X
X

X
X
X

X
X
X
X

X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X

Trans-vascular
Flow

Insulin
Delivery

Infusion
Sets

Pump
Therapy

X
X

X
X

X
X

X
X
X
X
X

X
X
X

X

X
X

X

X
X
X
X
X
X

X
X
X

X
X
X

X
X
X

X
X
X
X
X
X
X
X
X
X
X
X
X
X

X
X

X

X
X
X
X
X

X
X
X
X

X

X
X

X
X
X

X
X
X

X

X

X

X

X
X
X
X

X
X

X
X

X

X
X

X

X
X
X

X

X
X

X

X
X
X

X
X
X
X
X
X
X
X
X

X
X
X
X

X
X
X
X
X
X
X
X
X
X
X
X
X
X

X

X
X
X

X
X

X
X

X
X

X
X
X

X
X

X
X

X
X

X

X
X
X
X
X
X

X

X
X
X
X
X
X

X
X
X
X
X
X
X

X
X
X

X

X

X
X
X
X

X
X

X
X
X

X
X
X

X

X

X

X

X

X

X

X

X

X
X

X

X
X
X
X

X

X
X
X
X

In vivo/Ex
vivo

X

X

X

X
X
X

Drug
Uptake

X

X
X

Subcutaneous
Drug Delivery

X
X

X
X
X
X

X
X

X

X

X

X
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3. Methodology
Therefore, considering the background and discussed research, the main research
components were as follows:
First, a steady state porous media CFD model was developed to simulate the delivery of
insulin the subcutaneous adipose tissue space using the CFD software Star CCM+ developed by
Siemens Digital Industries Software. This model incorporated both the insulin being delivered by
a cannula as well as the interstitial fluid flow driven by the blood and lymphatic capillaries present
in adipose tissue. This model was able to obtain results similar to those found in previously
performed insulin delivery studies presented in published research [26, 46].
Secondly, a parametric study was completed using the CFD model in order to study how
different important factors of insulin delivery affect the delivery and dispersion patterns of the
drug in the tissue. These factors included the adipose region thickness and infusion set cannula
geometric design. These results were compared using post processing tools and graphics in the
Start CCM+ software as well as a design of experiments statistical analysis of the insulin depot
size formed in the adipose tissue model domain.
Through these steps of the study, conclusions concerning insulin delivery for Type 1
Diabetic patients were able to be drawn and discussed using the results obtained. The analysis of
the insulin delivery cases using the developed CFD model did produce results indicating the
cannula geometry and tissue thickness do both affect the kinematics of insulin delivery in the
tissue. Further, observations made from the results were able to indicate further investigation into
factors affecting insulin delivery would be warranted, as later discussed.
3.1 Research Goals
To accomplish the research components, a set of goals was set forth as follows in order to
build upon the published research as well as explore new applicable areas:
•

Develop a steady state porous-media CFD model for subcutaneous adipose tissue fluid
flow

•

Incorporate insulin infusion into the subcutaneous adipose tissue fluid flow CFD model

•

Compare the deposition and flow of insulin using current market cannula designs within
the known adipose tissue thickness range using the developed CFD model
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•

Complete a parametric study to analyze the effects of different cannula geometries and
tissue thicknesses on insulin deposition and dispersion
The first goal to develop a steady state model for adipose tissue fluid flow was a necessary

step to more accurately be able to simulate insulin flow into and through the tissue region. Having
an accurate model of how fluid flows through the interstitial space in the adipose tissue is essential
to accurately depicting the movement of insulin in the tissue. This was of great importance
especially in a time dependent study as it would drastically affect the dispersion over time of the
insulin. The previous studies that have looked at insulin delivery did not include this important
factor into the models that were developed though. Considering the results of previous research in
interstitial fluid flow in other tissue regions anatomically, the capillary driven flow would have a
direct impact on the flow patterns and dispersion of drugs being injected into the adipose region.
The vascularization patterns of adipose tissue also provided reason for the need to include
capillary exchange induced interstitial flow in an adipose tissue model, as the vascularization of
adipose tissue can be described as more meandering than patterned compared to muscular tissue.
Prior studies showed that the vascularization patterns in muscle and ligaments directly influenced
the flow velocities, directions, and even impact on cells in the tissue region, which would indicate
a direct impact on the flow of injected drugs into the tissue region as well [27-35]. Therefore, given
that the capillaries are more randomized in adipose tissue, this could be assumed to have a direct
impact on how drugs flow in the tissue. This indicates that the first step to building a CFD model
to study insulin treatments in Type 1 Diabetic patients would be to develop a CFD model that
properly models the fluid flow found in the adipose tissue without an insulin injection.
After a foundation model for the adipose tissue fluid flow was developed, the actual insulin
infusion could be added to the model. The results of prior studies concerning insulin infusion were
able to be used here to indicate whether the model developed did in fact give results that are similar
to what have been previously observed in insulin delivery. It should be noted these studies have
been completed using a pump at a much larger flow rate than was used in the cases of the current
study. Therefore, the higher insulin flow rate was used to verify the model with previous published
results but were not a significant component for the results of this study. The verification was able
to be done by reproducing the conditions of the study presented by Leuenberger Jockel et al. [26]
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as well as comparing the results obtained for the CFD model with the ex vivo results observed in
the previous ex vivo study.
Once the developed porous media CFD model was able to provide viable results compared
to previous published data, the current infusion sets were introduced into the model with the goal
of using this new model to accurately simulate insulin delivery with each cannula design used on
the market today. One of the biggest unknowns in current pump therapy is which infusion set to
use for each patient, let alone whether different anatomic locations on a patient should be used
with different infusion set designs to gain consistent treatment results. This has led to the current
trial and error approach, where an infusion set is used, and if it does not have an observable positive
effect on blood glucose control, another infusion set may be tried in an attempt to get better control.
Little study has been done actually to determine if simulations can viably indicate which infusion
set should be used for individual patients based on their individual body characteristics. A model
that looks at the different possible infusion sets paired with the different adipose tissue thicknesses
could be used to better understand where each infusion set design distributes the insulin paired
with different tissue thicknesses. This could give better insight into which infusion set should be
used for different body types, rather than having to go through the time-consuming process that is
currently used to decide which infusion set a patient should use.
Finally, a parametric design of experiments (DOE) study was instrumental in
differentiating whether the infusion set, tissue thickness, or both are significant in the insulin
delivery pattern. A combination of comparing generated graphical images of the insulin flow
development through the deposition area as well measurements of these areas were able to be used
to draw conclusions concerning how the factors of interest, namely cannula geometry and tissue
thickness, affected the insulin delivery. Using the DOE helped to understand the different trends
found in the results and helped to determine if the cannula geometry and/or tissue thickness was
significant factor in insulin deposition and dispersion. This led to the conclusion about potential
direct impact on current pump therapy, as well as indicating which areas warrant more research.
3.2 Case Studies
Considering these goals, a study set of twenty-five cases were designed, as presented in
Table 3, where there are 5 adipose tissue thicknesses that will be considered as well as 5 infusion
set cannula geometric designs. These case-studies were built around two major factors that have
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been suggested by previous research greatly impact subcutaneous drug delivery treatment success,
which are the cannula geometry (length and insertion angle) and the adipose tissue thickness.
These cases studies were built using a CFD model, as shown in Figure 6, that considers a domain
of adipose tissue modeled as a porous medium with capillary fluid exchange driving the fluid flow
in the tissue. It can be noted various elements of the model are shown here, including the capillaries
inducing the interstitial fluid flow in the model and velocity vectors indicating the interstitial fluid
flow direction and magnitude.

Figure 6. Adipose tissue fluid flow and insulin infusion CFD model domain and elements.
Based off the previously completed studies considering adipose tissue thickness in adults,
a range from 6.0 mm to 30.0 mm was found reasonable to encompass the average range of adipose
tissue thickness [48-50]. This includes the different anatomical areas used for insulin injections as
well as the range of body types from lean to obese. Considering this range of tissue thickness was
able to show whether insulin delivery can be affected by the thickness of the tissue it has been
delivered into, as well as indicate how the insulin disperses in the tissue. This is especially
important when considering different infusion set designs may result in better insulin delivery in
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different adipose tissue thickness ranges. A 6 mm tissue thickness step size was used between the
cases in each set to fully encompass the range of tissue thickness.
Table 3. Matrix of case sets and parameters.
Number of

Cannula Design

Tissue Thickness

Cases

(insertion angle x length)

(mm)

Set 1

5

90° x 8mm

6, 12, 18, 24, & 30

Set 2

5

45° x 13mm

6, 12, 18, 24, & 30

Set 3

5

30° x 13mm

6, 12, 18, 24, & 30

Set 4

5

20° x 13mm

6, 12, 18, 24, & 30

Set 5

5

20° x 17mm

6, 12, 18, 24, & 30

Another property that was involved in the modeling of the tissue that directly related to the
position of the cannula in the adipose tissue region was the thickness of the dermis layer above the
adipose tissue. Although the dermis thickness is variable anatomically just as the adipose tissue is,
it was assumed the dermis had a thickness of 2.5 mm for each case. This tissue thickness for the
layer found above the adipose tissue fits within the published study results looking at this
anatomical region of the tissue of 1185 μm to 3616 μm in human tissue [59]. It can be noted that
one case in Set 2, with the 6 mm adipose tissue, required the assumption that the dermis had a
thickness of 3.5 mm to keep the cannula within the adipose tissue without delivering into the
muscular region below. This assumption still fits within the published range as discussed above.
In considering the infusion set design, there are four typical insertion angles that are used
for subcutaneous cannula geometries used in insulin pump therapy internationally, which are 90degrees, 45-degrees, 30-degrees, and 20-degrees. It can be noted that there are some infusion sets
that are inserted without a guide, so the angle can be between one of these identified angles, such
as the Medtronic MiniMed™ Silhouette™, but the insertion angle range for this infusion set is still
20 to 45 degrees. Each pump manufacturer has these options in their infusion sets product lines,
varying only in either the locking mechanism on the infusion set or the cannula material and
diameter, but the insertion angle remains the same. Therefore, the presented insertion angles for
the cannulas should accurately represent the infusion sets that are available to Type 1 Diabetic
patients currently. Figure 7 indicates how the geometry of the different cannula lengths and
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insertion angles are defined for the infusion sets. The figure also shows this in reference to the
cannula being inserted in a tissue sample.

Figure 7. Cannula geometry definition with respect to adipose tissue.
Similarly, the cannula lengths are established across the market that correspond with the
different angles of insertion for specific infusion sets. Infusion sets designed for 90-degree
insertion typically have a cannula length of 6mm or 8mm. An 8mm to 10mm cannula length was
identified as the recommended general use cannula by health officials in a previous study, and
therefore an 8 mm cannula for the 90° insertion angle cannula geometry was used in the respective
cases [8]. Cannulas of infusion sets designed to have a more acute insertion angle come in the
lengths of either 13mm or 17mm across each pump manufacturers product lines in order to get the
depth required to get past the dermis and into the adipose tissue below. Most often endocrinologist
recommend the shortest cannula, as to alleviate the chance of intramuscular infusion from the
cannula passing through the target adipose tissue into the muscle below. It was therefore decided
to consider each of the more acute insertion angles as the shorter 13mm cannula length. In order
to still consider the longer 17mm cannula though in this study, it has been included as a second
20-degree insertion angle case, which would be the most likely candidate for the longer cannula
length because it has such an acute angle of insertion that the penetration depth into the adipose
tissue would still be only about 4.5mm.
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Each of these twenty-five cases would be considered using the injection rate of two of the
most common insulin pumps on the market today, the entire line of Medtronic pumps, and Tandem
t:slim X2 pump. This rate of delivery is 1.5 units of insulin (IU) per minute [60]. Although there
are slightly different insulin delivery rates in other pumps that are not as common on the market
as well as insulin pen injections, the main considerations of this study are to look at the infusion
sets and adipose tissue thickness. Therefore, the most common injection rate found in the current
insulin pumps available can be considered in each case. Also, the cannula for each case set was
assumed to be a 25-gauge size, which is standard for the infusion sets on the market such as the
Medtronic MiniMed™ Silhouette™ previously mentioned. Further, it was assumed across the
study that the cannula was perfectly seated into the tissue, and therefore no fluid could be lost
around the cannula and dermis interface. This was validated by the fact even in previous published
ex vivo insulin delivery studies, no leakage was observed around the infusion site [26].
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4. CFD Theory
CFD is a numerical method used to solve fluid flow problems in the areas of fluid flow,
heat transfer, chemical reactions, and even fluid and structure interactions. This computational
numerical method is based upon a set non-linear differential equations, which are derived from the
physic principles of conservation of mass, Newton’s Second Law, and the First Law of
Thermodynamics. Further, due to the structure of adipose tissue, the additional theoretical
solutions concerning porous media as well as porous media turbulence must also be taken into
account to make a viable computational model of the adipose tissue domain.
The fundamental of CFD therefore is considering constructing the model based off small
differential volume elements of fluid. These differential elements are used to create a discrete
domain in which the flow field can be solved for at each point on the differential element, while
the other areas are approximated by interpolation. Therefore, the discretized element can be
represented as shown in Figure 8, with its center at (x, y, z) and length of δx, δy, and δz in the
respective coordinate directions. Due to the small size of the elements in respect to the domain
being considered, the properties of the fluid flow can be accurately expressed in the first two terms
of a Taylor series expansion [61].

Figure 8. Control volume of differential element for discretized domain.
4.1 Conservation of Mass
The first principal equation governing CFD is the conservation of mass, as shown generally
in Equation 3 below, which is a scalar equation, indicating the solution is not direction dependent.
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The mass flow rate can be written in terms of fluid flow parameters, as shown in Equation 4:
(̇ = 456

(4)

Where (̇ is mass flow rate, ρ is the fluid density, V is the fluid velocity, and A is the area of the
control surface the fluid is flowing thru. Based on the directions of the fluid flowing in the
differential element and a Taylor series expansion, as shown in Figure 9, it can be shown that in
each coordinate axial direction there is one control surface with positive flow of mass into the
element, and one surface with a negative mass flow [61]. It can be noted that u, v, and w indicate
the flow velocity in the respective x, y, and z directions independently on the element.

Figure 9. Differential element for the conservation of mass.
The net rate of mass transfer across the boundaries of the element can be calculated by multiplying
the respective directional velocities by the differential areas of the surface, and subtracting the
mass outflow from the mass inflow, resulting in the total mass transfer as shown in Equation 5.
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This generalize solution for the conservation of energy can be simplified based on several
conditions of the fluid flow being considered. If the flow is steady, the time dependance of the
,

solution can be removed, since ,# = 0. Similarly, when a liquid is considered incompressible, that
,"

is the density is not variable across the domain, the density may be considered constant, so ,# = 0.
Although no flow is completely incompressible, in most cases where low velocities of air (below
Mach 0.3) or a liquid is being considered, it can be assumed the fluid is incompressible [61]. This
results in the differential equation describing the conservation of mass to be,
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as the density is constant across the domain being considered. This results in significantly less
computational requirements for each iteration of the model solution.
4.2 Conservation of Momentum
The second principal governing equation of CFD is Newton’s Second Law, or the
conservation of momentum. The generalized equation indicated that across the differential
element, momentum is conserved, as shown in Equation 7.
:2( &' '&*;$) = !"#$ &' (&($+#2( 0+;*$")$

(7)

Unlike the conservation of mass, momentum is a direction dependent equation, resulting
in three governing equations, one in each principal direction respectively [61]. Therefore,
considering the forces on each surface of the differential element, there is a stress component in
each principal direction, as shown in Figure 10. Each face has one pressure component
perpendicular to the face, and two viscous stresses parallel to the face.
The force on each of these surfaces is the product of the stress and the differential surface
area. Therefore, each face has a force corresponding to each principal axial direction, as
exemplified in Figure 11 for the x-direction stresses, where p denotes pressure. This results in the
net sum of forces for the x-direction be described as in Equation 8 below:
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Figure 10. Stress components on differential element surfaces.

Figure 11. Stress components in the x-direction on differential element.
The y-direction and z-directions are similar, only varying where the pressure term is found
in the equation with respect to the axis direction being considered. The rate of moment increase is
found by considering each principal axis direction related to momentum being the product of mass
and velocity,
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Therefore, the overall generalized governing equation for the x-direction would be as follows in
Equation 10.
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Where SM indicates body forces that act on the fluid, which would commonly include gravity and
other forces such as centrifugal, electromagnetic, and Coriolis forces [61]. In a practical
understanding, the right side of the equation accounts for all inertial forces, while the first
component if the left side is the normal pressure, and the second and third component of the left
side account for the shear forces on the differential element with respect to the x-direction. This
can be transferred to y and z directions, resulting in two more equations as shown in Equation 11
and 12.

=

=

!10!" 2
!'

!(0!# )
!'

>+=

>+=

!1-./0"" 2
!)

!10"# 2
!)

>+=

>+=

!10#" 2
!+

4(

> + :3) = 4 4#

!(-./0## )

4*

!+

4#

> + :3+ = 4

(11)

(12)

Several simplifications can be considered here too, based on knowing different fluid
properties or making assumptions. First, if the flow is incompressible,

,"
,#

= 0 again respectively.

Similarly, if the flow is only two-dimensional, one principal direction will be assumed negligible.
Lastly, if the flow is being considered as non-viscous, the shear components may be neglected as
friction is the cause for the fluid element shear stresses [61].
4.3 Conservation of Energy
The final principal equation governing CFD is the First Law of Thermodynamics, or
conservation of energy. General, this is defined as in Equation 13:
!"#$ &' ;ℎ"+G$ &' $+$*GC = !"#$ &' ℎ$"# "AA$A + !"#$ &' /&*H A&+$
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(13)

This general is a scalar equation, resulting in one more governing equation for the computational
model. The result is composed of considering the rate of heat flux across each surface and work
done on each surface. The result is a general energy equation, as follows in Equation 14.
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Where E signifies energy, q is the heat flux in the given direction, and SE is a heat source in the
fluid element. This equation is a general form, that can be converted to be written in terms of
temperature, enthalpy, internal energy, and kinetic energy [61].
This equation can be simplified by noting that if the fluid is frictionless, the shear stress
terms will be zero. Also, in isothermal cases, there will be no heat flux across the element
boundaries, resulting in the heat flux term being zero.
4.4 Porous Media
A porous medium is described as a medium whose volume is composed of a solid matrix
of material with an interconnected void throughout the domain [62]. The main factor in the material
is the porosity, or ratio of the void space to the total volume of the solid. A very important factor
in porous media modeling, especially in medical CFD modeling, is the tortuosity, which is the
resistance to diffusion of the flow by local parameters such as viscosity or boundaries [62]. This
porous media modeling has been used as a means to understand and predict heat transfer in human
tissue, as well as transport models around or within biologic tissue [33, 35-45, 62-64]. The
utilization of porous media models has allowed for useful description of different biological
functions and have been found to have an abundance of applicable areas in medical applications
especially related to tissue regeneration and even drug transportation [62].
4.5 Navier-Stokes Equations
The previous equations do form a set of differential equations that could solve for fluid
flow but fail to yield a solution for the viscous shear stress components. However, these viscous
stress components can be related to the principal direction velocity components u, v, and w. Under
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the assumptions that the fluid is isotropic and Newtonian, the Navier-Stokes equation can be
applied down to a microscopic scale [61, 65]. The Navier-Stokes equation is defined as follows in
the independent x, y, and z directions of the domain,
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Where μ is the dynamic viscous friction of the fluid, and in a steady state !# = 0 and if there are no
body forces such as gravity SM is also zero. In considering porous media, the Reynolds number
should be considered also, as with a small Reynolds number (Re <<1), the Navier-Stokes equation
can be simplified to just the Stokes equation since the inertial forces are small compared to the
viscous forces [28, 33, 42, 40, 62, 65, 66]. Therefore, the set of equations 15, 16, and 17 becomes
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with the assumption there are also no body forces affecting the fluid flow as well.
4.6 Darcy’s Law
In considering porous media, the Navier-Stokes equation can be applied to the flow inside
the pores of the media but cannot be applied in a generalized form to the entire macroscopic media
domain [66, 67]. Considering a steady state isothermal Newtonian fluid flow in a porous material
51

though, the governing equation called Darcy’s law can be applied [28, 33, 42, 40, 62, 65-67].
Darcy’s law indicates there is a linear proportionality between flow velocity and the applied
pressure difference [62]. The model is expressed by:
!.
!'
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Where K is the permeability of the porous medium or Darcy number, and 2O is the Darcy velocity
(the fluid velocity average across the cross section) [62]. It can be noted Darcy’s model can be
obtained by simplification of the Navier-Stokes equation for a porous medium, or by starting with
the Brinkman system in a porous medium with a very small Darcy number [28, 33, 42, 40, 65].
The Darcy model is therefore a good prediction when considering media with very low
permeability and low Reynolds numbers.
4.7 Turbulence Modeling in Porous Media
Although turbulent flow in porous media is often present, and even in case a design factor
in CFD studies, there is a significant lack of published literature in this area [68]. In order to
understand what the turbulence in a porous material may look like, or even if there would be
significant turbulence to be considered, the Reynolds number of the system must be established.
The most generalized form of considering the Reynolds number in relation to turbulence in a
porous media is known as the pore or particle Reynolds number defined as:
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where ReP is the pore Reynolds number, U is the intrinsic average velocity, and dP is the average
pore diameter (or be assumed the particle diameter) [68]. There is also a definition of the Reynolds
number based upon the Darcy number, which is as follows:
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Where ReD is the Darcy Reynolds number [68]. Due to the structure of porous media, and the small
scale, different microscale flow field properties can be defined based on the estimated Reynolds
numbers of the system. There are 5 major ranges that have been presented, as shown in Table 4
below.
Table 4. Different regimes of porous turbulence based on Reynolds number [68].
Regime

Reynolds Number Range

Darcy Regime

ReP < 25, ReD < 10

Inertial Regime

25 < ReP < 375, 10 < ReD < 150

Unsteady Laminar

375 < ReP < 750, 150 < ReD < 300

(transitional) Regime
Turbulent Regime

750 < ReP < 3,400, 300 < ReD < 1,360

Asymptotic Regime

ReP > 3,400, ReD > 1,360

Each regime has a different flow field associated with it but is quite qualitative based on
rough Reynolds number criteria ranges. The Darcy regime can have the flow field approximated
very well by Stokes flow with no significant turbulence. In the inertial regime, inertial effects of
the fluid begin to appear, with very different velocity profiles compared to the Darcy regime with
even some steady vortical structures having been observed in this range. Unsteady transitional
flows are observed in the Unsteady Laminar regime, with periodic vortexes and even some
exhibition of intermittency. The Turbulent regime is where the flow within pore spaces begins
follow the characteristics of typical turbulent flows. Finally, in the Asymptotic regime, turbulence
is able to be approximated as being isotropic over the majority of the pore volume [68].
4.8 Ergun Equation
Considering the adipose tissue could be considered a packed bed of adipocytes in this
modeling case, giving rise the description of the flow of the fluid past the adipocyte in the domain
by the Ergun equation. While Darcy’s Law applies to creeping flows, as would be observed in
adipose interstitial fluid that has a Reynolds number much smaller than 1, as previous research has
mentioned, the relationship between the pressure gradient and flow velocity becomes much more
nonlinear as flow velocity increases [28, 35, 40-45]. This would apply to the area around the
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injection site in adipose drug delivery, as the drug would have a much higher velocity while being
delivered than the interstitial fluid. To account for this change, Dupuit and Forchheimer proposed
the addition of a quadratic term known as the Forchheimer, as shown by Equation 25 [69].
9
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Where ∇Q is pressure differential and b is a factor dependent upon the particular flow and medium
(normally determined through experimentation) [69]. The Ergun equation is a specific example of
this Forchheimer equation, which is an empirical model to describe the pressure drop over a length
of the domain through a packed bed [70]. This is described as shown in equation 26:
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where Pv is the viscous term and Pi is the inertial term. Therefore, it can be scene comparing
Equations 25 and 26 that the permeability and b factor can be described as follows:
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Therefore, the use of the Ergun equation can be applied to the case of injecting insulin into the
adipose tissue considering the relatively large velocity of the insulin entering the tissue compared
to the interstitial fluid velocity as well as the adipocytes being constructed in the tissue similar to
a packed bed.
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5. Domain and CFD Model Development
The Domain and CFD models were developed using a combination of physical
measurements, previous study principles and results, and justified assumptions based on known or
published biological factors. The model was developed using first known values for parameters
such as specific adipose tissue and capillary characteristics. The unknown or assumed parameters
that may have an influence on the flow and results of the model were studied individually, to
determine what would create the most accurate outcome based on previous studies as well as know
kinetics of interstitial flow and insulin delivery. These developments and parameters are discussed
in further detail in the following sections. The evolution of the presented CFD model took several
iterations to compare results and refine the design as well as input parameters to accurately model
the interstitial flow and deposition of insulin into the model.
5.1 Domain Modeling
The model domain was created using the SolidWorks 2018 software package. The first
consideration required in the development of the model was determining of the domain size. The
thickness of the adipose tissue sample domain would vary by the tissue thickness range being
studied as discussed in the cases, but the length and width of the domain would remain the same
for each simulation case. Based on the cannula designs and anatomical measurements with an
infusion set inserted, it was determined that a domain size of 120 mm x 100 mm would be
sufficiently large to give acceptable results in the simulation. Further validation of this would be
that 120 mm was about ten times greater than the insulin deposit outreach overserved in previous
research [26].
One of the most important factors in the domain size was keeping the domain large enough
to reduce the chance for domain induced anomalies, but small enough that the micro-scale mesh
could be refined enough and remain computationally feasible. The domain size of the adipose
tissue sample was further refined by considering which shape domain resulted with expected
interstitial flow. The three domain shapes considered were a rectangular domain 120 mm x 100
mm, a 120 mm square domain, and a round domain with a 120 mm diameter. Each of these domain
shapes tested can be seen in Figure 12.
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After running a simulation on each of the trial domains, as seen in Figures 13-15, it was
able to be concluded that the round domain would be the selected choice for the CFD model being
developed for interstitial fluid flow.
The first indicator of this was that compared to the rectangular domain, there was a higher
mesh volume element to domain volume ratio, as the circular domain had a similar number of
mesh elements to the rectangular domain, even though it had a 6% decrease in volume compared
to the rectangular domain. The square domain on the other hand had a 16% increase in mesh
volume elements, which would be expected as the volume of the square domain was 20% larger
than that of the rectangular domain. Therefore, the round domain could be said to have the most
efficient use of resources based on volume elements, which was a major factor in the design of the
model.

(a)

(b)

(c)
Figure 12. Three tissue domains tested for interstitial adipose fluid flow. (a) 120 mm x 80 mm
rectangular domain (b) 120 mm square domain (c) 120 mm diameter round domain.
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Secondly, there was no noticeable change in fluid flow between the domain shape options,
as shown by the velocity profiles in Figures 13-15.

Figure 13. Adipose fluid flow trial with 120mm x 100 mm rectangular domain.

Figure 14. Adipose fluid flow trial with 120mm square domain.
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It can be noted the only major difference observed was between the round domain and the two
other domains, which was the stagnant area of flow in the corners of the flat side domains.

Figure 15. Adipose fluid flow trial with 120mm diameter round domain.
This would be expected due to the characteristic of fluid flowing out of a corner of a domain but
would not be necessary for the consideration of this study, and therefore could be considered an
inefficient use of volume in the domain. Because of this, the round domain again can be said to be
the more efficient domain shape for considering the interstitial fluid flow in adipose tissue and
insulin deposition.
The other major consideration with the design of the adipose tissue domain was how the
capillaries should be modeled to induce the interstitial fluid flow in the CFD model. The biggest
difficulty was that the capillaries in the adipose tissue have a lumen diameter of 2-10 μm, which
is extremely small to model in both the CAD and CFD environments [71, 72]. Also, along with
the micro scale of the capillaries was unpredictable pattern of capillaries found in adipose tissue.
Therefore, there were three options looked at for the model, the first being assuming the fluid flow
was induced through the faces of the domain. This meant that a combination of the upper and
lower surfaces of the modeled tissue sample (representing the lower layer of the dermis on the top
and muscular bed on the bottom) and the side faces would be used as velocity inputs in the CFD
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model to drive the flow through the porous media domain created. An example of what the fluid
velocity pattern noted in the model domain with this type of interstitial flow induction can be seen
in Figure 16.
The second and third options involved modeling the capillaries throughout the domain to
drive the interstitial flow, represented as either a repeated pattern across the domain or a
meandering path through the domain. After creating a volume mesh for several trial CFD models,
a capillary lumen diameter of 0.25 mm was found to be the smallest diameter able to be meshed
feasibly with the computational resources available, as later discussed in section 5.6 respectively.
This lumen diameter is much greater than anatomically correct 5-10 μm diameter, but was
concluded acceptable based upon the limited computation resources available and the variability
that would be found in the vascularization of adipose tissue throughout the body [4, 51-53]. The
second way to model the capillaries was geometrically repetitive across the domain, such as a
lattice pattern going from one end of the model domain to the other as well as across from side to
side, while inducing a flow from using the capillary walls as a velocity output. An example of this
flow induction can be seen in Figure 17. The final option was to model the capillaries in a much
more randomized manner across the domain, utilizing 3-dimensional splines, as is shown in Figure

Figure 16. Capillary exchange induced interstitial flow from top and bottom faces.
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18. Using 3-dimensional splines would be a much more anatomically correct representation of the
capillaries found in adipose tissue, but much more time consuming and resource heavy to model.
The figures of the different capillary induced flow models show there was drastic
differences noted between each type of capillary design simulated for the model. First, the flow
induced from only the top and bottom face of the model developed such that as the flow moved
through the domain, the flow in the central region across the domain increased in velocity as well
as becoming more compact as it reached the outlet face.

Figure 17. Lattice modeled capillary exchange induced interstitial flow.
It can be noted that the model was simulated with influx fluid velocity from the top and
bottom faces only, with the side faces as symmetry planes and the rear face an outlet. This could
be described as very similar to what would be seen in a pipe, with a boundary layer developing
across the flow domain on the walls. However, this very developed boundary layer and pipe style
flow would not be expected in a sample of adipose tissue with the interstitial fluid flow induced
by capillaries running throughout the tissue. Also, there was about a ten times greater maximum
velocity magnitude in the fluid flow than the other models trialed, which could likely be attributed
to the large surface area acting as a fluid inlet. It was able to be concluded from this that inducing
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the flow from faces on the domain, though computationally less taxing, was not the most accurate
method to model the adipose tissue interstitial fluid flow.

Figure 18. Spline modeled capillary exchange induced interstitial flow.
Considering the lattice hatched pattern model of the capillaries throughout the tissue
domain, it can be seen there was a very geometrically symmetric flow induced by this type of
design. The flow across the domain was very patterned based on the flow velocities coming out of
the capillary walls across the model. This was much closer to what would be expected based on
prior published studies as well as adipose tissue characteristics compared to flow being induced
from the top and bottom of the tissue domain. The flow was much too patterned throughout the
domain though to be the most accurate representation achievable in a model of adipose tissue fluid
flow.
Therefore, the selected representation of modeling the capillaries in the adipose tissue for
the presented CFD model would be using 3-dimensional splines. Although computationally splines
are much more computationally costly, it can be seen in Figure 18 that the flow pattern induced by
the capillaries being modeled as splines produces a much less repetitive flow development
throughout in the tissue domain. Using 3-dimensional spline creates a much closer representation
of what tissue studies have revealed the pattern of vascularization in the adipose region
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anatomically looks like [4, 51, 52]. Further, the flow developed across the domain as was described
to develop on a smaller scale by previous studies of interstitial fluid flow within subcutaneous
tissues [42, 73]. For these reasons, the 3-dimensional spline representation of the capillaries was
selected for the representation of the capillaries in the developed CFD model.
Using these previously discussed sizing and capillary criteria, the five tissue domains to be
used in each of the case sets designed was created. These domains for each respective tissue
thickness are shown in Figure 19.
The domains were generated in a manner to reduce the chance for a difference in the
capillaries in each of the domains to greatly affect the results of the CFD simulations between the
different tissue thickness domains. This was done by creating 35 capillaries of 0.25 mm in diameter
that were non-intersecting and well distributed within the 6 mm adipose tissue domain. The 12
mm tissue domain was then created from this 6 mm domain by extruding an extra 6 mm of
thickness onto the domain. The existing capillaries were then geometrically repositioned in the
new 12 mm domain to be roughly equally distributed in the domain depth again. There were three
more capillaries added to reach a better distribution through the tissue domain, resulting in the 12
mm, 18 mm, 24 mm, and 30 mm tissue domains a total of 38 capillaries distrusted in the adipose
tissue model. This extrusion and redistribution process was repeated until the 18 mm, 24 mm, and
30 mm adipose tissue domains had been generated. Developing each adipose tissue domain in this
manner greatly reduced the variability for flow differences due to drastically different
capillarization patterns.
Using the above-described process to generate the tissue domains did allow for the
capillarization pattern to remain very similar across the five tissue thicknesses, but it did also result
in a reduction in capillary density in the tissue domain from the 6 mm tissue to the 30 mm tissue
models. This phenomenon of a lower capillarization density in the thicker adipose tissue would be
anatomically correct though, and therefore was assumed to be acceptable in this study [53].
Similarly, since the pattern in which adipose tissue is vascularized has not been well quantified
and has been shown to be variable within and across individual patients, it could be assumed the
generated capillary pattern for the domains would allow for viable results in this study [4, 51, 52].
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(a)

(c)

(b)

(d)

(e)
Figure 19. Adipose tissue domains with capillaries (a) 6 mm thick (b) 12 mm thick (c) 18 mm
thick (d) 24 mm thick (e) 30 mm thick.
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5.2 Capillary Exchange Driven Flow
One of the most critical components to the model is the interstitial flow through the tissue.
This flow is driven from the exchange of fluid between the interstitial space and vascular and
lymphatic capillaries, as previously discussed. Therefore, the flow direction and velocity through
the tissue is directly driven by this exchange between the capillaries and interstitial space. In the
model, this velocity could be simplified by considering the relationship between velocity, capillary
permeability, and hydrostatic and osmotic pressures shown in Equation 29 [28, 33, 42]:
2) = HJ [(QJ − QB ) − (VJ − VB )]

(29)

Where uy is flow velocity from capillary, kc is capillary wall permeability, pc is hydrostatic pressure
in blood, pi is hydrostatic pressure in interstitial fluid, πc is osmotic pressure in blood, and πi is
osmotic pressure in interstitial fluid. The published properties to find the characteristic velocity of
the flow coming out of the capillary at both the venule and arteriole side of the capillary are found
in Table 5. Given these parameters, the characteristic output velocity range of fluid across the
capillary wall can be calculated at the arteriole and venule ends of the capillaries in the tissue. This
would be assuming the interstitial pressure is constant across the domain of the tissue, which
considering the tissue sample is macro sized, the assumption of constant interstitial fluid can be
stated to be valid.
Given equation 25 and the parameters of Table 5, the characteristic across capillary wall
velocity range can be said to be 1.33 μm/s to -0.665 μm/s from the arteriole to venule ends of the
capillary. It can be noted that although there are both venous capillaries and lymphatic capillaries
in the adipose tissue, the physiological parameters of both are very similar, but a large difference
in the fact that lymphatic capillaries only have an uptake of interstitial fluid [74, 75]. The lymphatic
system only uptakes about ten percent of the fluid transferred between the vascular system and the
interstitial space [76]. The lymphatic system would therefore have a significantly lower impact on
the interstitial fluid flow. Therefore, the assumption was made for this study that the capillaries of
the domain were all modeled to have venous capillary physiological and transfer properties.
The flow velocity from the capillaries into the adipose tissue can be assumed linear across
the length of the capillary, as demonstrated in prior studies, being able to be described by Equations
30 and 31 [28, 33, 41, 42].
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Table 5. Physiologic parameters of capillaries and fluids [33].
Parameter

Value

Permeability coefficient of
capillary’s wall (kc/(m •s•kg ))
2

-1

5 ´ 10-10

Plasma colloid osmotic pressure

3.72

(πc/kPa)
Interstitial fluid colloid osmotic

0.67

pressure (πi/kPa)
Pressure at the arteriole section of

5.32

capillary (pa/kPa)
Pressure at the venule section of

1.33

capillary (pv/kPa)
Hydrostatic pressure of interstitial

-0.40

fluid (pi/kPa)
2) = 2E −

2A = 2E +

%(
A

B

%) /|K* [(.+ -., )-(M* -M, )]|
A

(30)

B

(31)

Where u0 is characteristic maximum velocity, uL is velocity at x along the capillary, L is capillary
length, and x is position length along capillary. This velocity profile was able to be used to drive
the interstitial adipose tissue fluid flow in the model based on the position within the model
domain. Since the capillaries were modeled to stretch the length of the domain, the capillary
exchange velocity described was further modeled as a sinusoidal pattern for some of the capillaries
in the model. This reduced velocity patterning noticed in early models where stagnation regions in
the domain were created from assuming only the linearized exchange velocity profiles (as shown
by Figure B-1 in Appendix B). The three resulting flow velocity magnitude curves based upon the
length direction domain position used in the CFD model simulations can be seen in Figure 20
respectively. It can be seen that one linearized profile was created starting at the front of the domain
and one at the back of the domain. The capillary exchange velocity profiles were also used to
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described three additional capillary groups dependent upon the position across the domain rather
than the length of the domain.
This flow pattern was also found to produce interstitial fluid flow velocities in the adipose
tissue model domain consistent with those published be associated with interstitial flow, which
would be in the range of 0.1-4.0 μm/s [35]. Therefore, it could be said that this velocity profile
was adequate to induce a fluid flow in the porous media model that was within the range of what
would be expected to be observed in the adipose region of tissue anatomically.

Figure 20. Capillary velocity output curves to generate interstitial flow in domain.
5.3 Model Parameters Identified
There were specific parameters that were able to be identified from previous publications
or mathematical models needed for the generation of the presented CFD model. These can be
found in Table 6 and Table 7 respectively. The major parameters needed pertain to the adipose
tissue itself, and characteristics of interstitial fluid and insulin to fully define the domain for
accurate flow simulation.
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Table 6. Adipose tissue model parameters.
Parameter

Value

Porosity

0.2 [77]

Density (kg/m3)

916.6 [78]

Specific Heat (J/kg-K)

2348 [79]

Thermal Conductivity (W/m-K)

0.21 [79]

Tortuosity

1.221

Interstitial Fluid Density (kg/m3)

1000 [28, 30, 41, 42, 46]

Interstitial Fluid Viscosity (kg/m-s)

0.001 [46]

The porosity of the adipose tissue was one of the most important characteristics to identify,
as the porosity of the tissue was the main component to creating the porous media domain, and the
largest factor affecting the flow development. The tortuosity of the tissue was not able to be found
as a readily available value, with ranges from 1.062 to 1.542, but using Equations 1 and 2 in
conjunction with the porosity of the adipose tissue, a reasonable tortuosity was able to be
determined [55, 57]. This calculation looks as follows, starting with Equation 2 to estimate the
diffusion permeability:
O

O

X = P-F = P-E.EO = 0.67114

(32)

And this diffusion permeability estimate can be used in Equation 1 to result in an estimation of the
square tortuosity:
C

C

]O = Q = E.RICCS = 1.49

(33)

Taking the square root of this results in the best estimate for the tortuosity of the tissue:
] = √]O = √1.49 = 1.221

67

(34)

Therefore, the best estimation for the tortuosity of the presented porous media CFD model for
adipose tissue interstitial fluid flow would be 1.221. This estimate does fall within the range of
published values estimated in studies previously mentioned as well.
Table 7. Insulin model parameters.
Parameter

Value

Insulin Density (kg/m3)

998.2 [46]

Insulin Viscosity (kg/m-s)

0.001 [46]

Insulin Mass Flow Rate (kg/s)

2.2125 ´ 10-7

Both the given values for the interstitial and insulin densities shown are accurate to each
of the respective fluids, but the assumption can be made that both interstitial fluid and the insulin
drug being injected have the density of saline at 1000 kg/m3. Interstitial fluid is composed almost
entirely of water and sodium that permeated the capillary walls into the interstitial space with its
solutes such as hormones, neurotransmitters, and glucose. Therefore, interstitial fluid was assumed
to have the same density as saline, given it its composition. This assumption was also made in
prior studies as well [28, 30, 41, 42, 46]. Similarly, the injected insulin drug is a composite of the
insulin hormone dissolved into saline giving it near the same composition as interstitial fluid with
only one hormone solute instead. Therefore, the assumption of the insulin drug solution having the
density of saline was justified for the use in the model. This assumption was further able to be
justified by the fact both interstitial fluid and insulin have negligible different in their fluid
viscosity compared to saline.
For the use of simplifying the insulin delivery in the model, a unit conversion from the
typically defined insulin delivery unit for infusion pumps of IU per minute was used to define the
insulin delivery rate as a mass flow rate in the CFD domain instead. Therefore, the unit conversion
from the previously define pump delivery rate of 1.5 IU/min for the case studies resulted in a mass
flow rate from the cannula to the adipose tissue interstitium of 2.5125 ´ 10-7 kg/s of insulin. This
full conversion of units can be seen in Appendix A.
A further assumption made about the adipose tissue was that it can be modeled as a bidirectional anisotropic medium. Although previously discussed, the arrangement of the adipocytes
gives a very uniform geometry, adipose tissue has an extracellular matrix that is the connective
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tissue giving the region its structure [5, 33, 41, 42, 54]. The region is geometrically very similar
volume filled with spheres, but as shown by previous ex vivo research, the way insulin depots
form during infusion follows channels that appear to form at the end of the cannula in the
extracellular matrix parallel to the muscular and dermis boundaries. Therefore, although the
adipose tissue region would have some isotropic properties, the assumption was made that the
region had a combined porosity of 0.2, with respective porosities of 0.25 in the x-direction and zdirection and 0.15 in the y-direction of the model domain. This anisotropic assumption was
previously show by Zedelmair to produce similar stagnant deposition results to that of previous ex
vivo studies [25, 26, 46].
5.4 CFD Model Physics
The choices of the physics in the CFD software were very important to create an accurate
simulation model for the tissue domain model created. The physics used to define the CFD model
and domain are shown below in Figure 21. First in the physics parameters would be the assumption

Figure 21. CFD model continua physics settings.
that the domain was all a constant density. Based on the previously discussed characteristics of
adipose tissue as well as the assumption that the infusion set was placed in an ideal position
anatomically, constant density in the model would be a valid assumption.
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The next important physics parameter that had to be determined for the model was whether
the flow needed to be modeled as turbulent or could be assumed to be a laminar flow. The
previously published studies on CFD modeling of interstitial flow had all assumed laminar flow,
but this assumption could also be proved by considering Equation 23 in relation to porous media
models and turbulence [28, 30, 41, 42, 68]. The parameters necessary to solve the theoretical pore
Reynolds number, ReP, are already known for the fluid and tissue. This includes the interstitial
fluid density (1000 kg/m3), interstitial fluid viscosity (0.001 kg/m-s), and particle diameter, which
would be 80 μm for the adipocytes in the adipose tissue [46, 80]. Therefore, the only parameter
that was needed to solve the pore Reynolds number was the intrinsic average velocity, which could
be found from simulating the model. This intrinsic average velocity was able to be found by
looking at the average velocity of the fluid leaving the domain of the adipose tissue in the CFD
model. The pore Reynolds number was found as follows:
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= 3.094472

(35)

Since this value of 3.09 is significantly lower than 25, that classifies the flow as being the Darcy
regime, which indicates laminar flow. Therefore, the assumption of laminar flow was able to be
justified further for the model by not only considering the assumptions of previous publications,
but also considering the flow properties of the trial CFD models create [28, 33, 41, 42]. It can be
noted that even if this calculation shown in Equation 30 was completed assuming the maximum
velocity seen in the CFD model of 7.54 × 10-2 m/s, the resulting pore Reynolds number of 6.029
would still be within the Darcy regime as well.
Considering the liquid and porous media components of the physics in the CFD
environment, the liquid was considered assumed to be water and the adipose tissue medium was
created. The assumption of water for both the interstitial fluid and insulin was used based on the
previously justified grounds. The adipose tissue medium was created for the porous region based
on the identified characteristics of the tissue as presented in Table 5 above respectively. The
domain was set to be a porous media domain, as well as be in thermal equilibrium. Thermal
equilibrium could be assumed as both interstitial fluid, adipose tissue could be said to be body
temperature. Similarly, since the insulin in the pump would be at room temperature, and since the
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tubing between the pump and infusion set would likely be in direct contact with the body due to
being routed between clothing and skin on the patient, the insulin could be assumed to be roughly
the same temperature as the tissue and interstitial fluid.
The final several parts of the physics continua of the CFD domain were set based on many
of the previously discussed properties of the model being designed. First, segregated flow could
be assumed since the Mach number of the flow velocity was much lower than 0.2 as well as the
model fluid being a liquid and therefore can be assumed incompressible. Similarly, segregated
fluid isothermal could be used due to the temperature similarities between all the components of
the model, the tissue, interstitial fluid and drug, as discussed previously. The model was set to
steady in order to look at overall average trends in the flow structure of the interstitial tissue as
well as insulin delivery. Though the model would be suitable to simulate time-dependent insulin,
due to computation resources available, as well as the study being designed to compare the effect
of cannula geometry and tissue thickness on the trends of insulin delivery, a steady state model
was acceptable. Finally, the model should have a 3-dimensional flow, as the capillaries have been
modeled as splines in a 3-dimensional domain representing the adipose tissue.
5.5 CFD Model Boundary Conditions
Considering the boundary conditions of the model, there were several different
experimental simulations with various boundary conditions that were trialed during the domain
shape development trials previously discussed during the development of the CAD model. It
should be noted that throughout all the trials although the muscular and dermis layers bounding
the top and to bottom of the adipose region were assumed to be solid boundaries even though
anatomically, they as well as the adipose subspace are deformable tissues. These trials with various
boundary conditions in different model domain shapes helped to develop the overall presented best
domain design as well as boundary conditions, as further discussed in this section.
Initially, the boundary conditions were set up very basic in rectangular prism porous
medium model, as shown in Table 8. The velocity of the inlet face on the domain was varied in
the range of 7.5 × 10-7 m/s to 1.00 × 10-5 m/s in order to achieve a flow velocity through the
domain on the within the published interstitial velocity range of 0.1 μm/s to 4.0 μm/s [35]. Also,
it should be noted pressure outlet in STAR CCM+ works non-constraining boundary, allowing the
domain to act as a sample of adipose tissue being considered within larger region of the tissue.
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These conditions were set as an initial way to start working with the porous media block to be a
baseline as the CFD model continued to develop. What was noted in these early simulation trials
was that driving the flow from a one side to the other side of the domain with one outlet face
induced a flow pattern as would be seen in a rectangular tube even considering the domain was a
porous medium. A rather thick boundary layer developed on the top and bottom face representing
the bottom of the dermis and muscular region respectively. A boundary layer would be expected
here, as the interstitial fluid would be expected to flow within the adipose region easier due to the
very low permeability of connective tissue between both the adipose tissue and the muscular bed
below and dermis above the adipose tissue. The core of the flow in the rectangular prism section
developed a high velocity between the boundary layers as would be expected in a rectangular pipe,
and the flow direction was all parallel out the outlet side of the domain.
Table 8. Early boundary condition for a rectangular shape CFD model.
Domain Face

Condition

Front

Velocity Inlet

Sides

Symmetry Plane

Top and Bottom

Wall

Back

Pressure Outlet

What was observed in these early trials was that the fluid flow was very patterned as
previously discussed due to the capillary design assumptions. Where this also played a part in the
development of the boundary conditions was considering that the flow would not be expected to
enter the dermis or muscular regions above and below the domain, but the entire region around the
domain would be a continuation of the tissue. Since this continuation of the tissue would be
anatomically present outside the model domain being considered, the outer face around the
cylindrical tissue domain would be well suited as pressure outlet rather than constraining the
interstitial fluid to exit just one side of a rectangular tissue domain.
Also, along the lines of having one pressure outlet not being ideal for the simulation, the
sides being constrained as symmetry planes was not the most accurate choice for the CFD model.
In considering the anatomic space being considered this also makes sense, as the flow in the body
may have a net direction in the interstitial space, it would still be expected that the flow be able to
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have a component in different directions, especially when nearing another capillary or cell that are
exchanging fluid from the interstitium. Therefore, the boundary constraints that were selected for
modeling this tissue sample of adipose tissue are as presented in Table 9.
Table 9. Adjusted boundary condition for adipose CFD model.
Domain Face

Condition

Front

Pressure Outlet

Sides

Pressure Outlet

Top and Bottom

Wall

Back

Pressure Outlet

Capillaries

Velocity Inlet

It could be noted that at this point in the CFD model development trials, it had been
determined that the interstitial fluid flow in the tissue was best driven from the modeled faces of
3-dimensional spline capillaries as previously discuss in the domain modeling section. Following
the conclusion these presented boundary conditions were a viable anatomical representation that
could be achieved in the developed CFD model for fluid flowing in adipose tissue. The different
shape domains and inlet velocity profiles were trialed as previously discussed with the boundary
conditions shown in Table 10. As shown in Figure 22 below, the fluid flow in the tissue sample
had exiting flow on every face, with general trends due to localized capillary flow, which would
be expected in this macro scale flow due to the porous media as well as the capillary outlet and
inlet of fluid [68, 80, 81].
Considering these noted justifications for the boundary conditions after trialing several
different combinations for the developed CFD model, the finalized set of selected boundary
conditions for the model are found in Table 9. These boundary conditions are stated in conjunction
with the round geometry for the domain previously discussed as the best choice for domain shape.
It can be noted there are six capillary groups in the table, each of which would have a different
fluid velocity inlet profile as previously discussed.
The first would have a linearized profile described by the maximum characteristic inlet
velocity induced by the osmotic pressure interface of 1.33 μm/s being at the front of the model
domain, and the second being the opposite with the minimum characteristic inlet velocity induced
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by the osmotic pressure interface of -0.665 μm/s being at the front of the model domain. The third
capillary group would have a sinusoidal fluid velocity inlet pattern as shown in Figure 20. The
fourth, fifth, and sixth capillary groups mirrored the prior three groups, only differing in their
dependent being the width dimension rather than length.

Figure 22. Adipose fluid flow trial with 120mm x 100 mm rectangular domain with all x and z
axis sides as pressure outlets.
Table 10. Finalized boundary condition for adipose CFD model.
Domain Face

Condition

Outer Face

Pressure Outlet

Top and Bottom

Wall

Capillary Group #1

Linearized X-direction Velocity Inlet (Forward)

Capillary Group #2

Linearized X-direction Velocity Inlet (Backward)

Capillary Group #3

Sinusoidal X-direction Velocity Inlet

Capillary Group #4

Linearized Z-direction Velocity Inlet (Left)

Capillary Group #5

Linearized Z-direction Velocity Inlet (Right)

Capillary Group #6

Sinusoidal Z-direction Velocity Inlet

Cannula Outlet Face

Mass Flow Inlet (average velocity inlet)

Cannula Wall

Wall
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These boundary conditions can further be identified in the CFD model domain as shown
in Figure 23. It should be noted that the capillary groupings were randomly ordered while making
the adipose tissue domain models and selected when creating the CFD model. This was done to
keep any geometric or patterned anomalies that might affect the fluid flow to a minimum. The
capillary groups were uniform between each different tissue thickness domain in the CFD
simulation to reduce insulin flow anomalies due to varied interstitial fluid flow between the
domains. It should be noted the cannula outlet was modeled as mass flow inlet into the adipose
region, which was averaged across the surface and does not account for flow development in the
tube between the pump and cannula prior to infusion into the tissue. This was assumed to be a
negligible consideration in this study though since the current pumps on the market utilize an
incremental delivery approach. This means that the insulin is stepped through the tubing over the
course of the insulin bolus, without fully developing a characteristic tube flow pattern in the tubing
or cannula that would be seen if it were a continuous flow delivery. Using these boundary
conditions resulted in the fluid flow demonstrated in Figure 15 previously shown in section 5.1.

(a)

(b)

(c)

(d)

Figure 23. Boundary conditions in CFD domain of adipose tissue model with cannula (a) outer
face (b) capillary group #1 (c) capillary group #2 (d) capillary group #3.

75

(e)

(f)

(g)

(h)

(j)
(i)
Figure 23 cont. Boundary conditions in CFD domain of adipose tissue model with cannula (e)
capillary group #4 (f) capillary group #5 (g) capillary group #6 (h) cannula outlet (i) cannula wall
(j) top and bottom.
A further component within the consideration of the model boundary parameters was
applying the anisotropic porosity condition. The overall model porosity was set at 0.2, but the
anisotropic component was incorporated using the application of the Ergun equation, using
Equations 27 and 28 for the respective inertial and viscous conditions. Therefore, when the viscous
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and inertial terms of the Ergun equation were utilized in the models, two field functions in the Star
CCM+ software were created for both the viscous and inertial terms. One function to be applied
in the x and z principal tensor directions with a porosity of 0.25, one function to be applied in the
y principal tensor direction with a porosity of 0.15. This allowed for the incorporation of the
anisotropic conditions that have been previously published regarding the insulin delivery
environment, especially around the end of the cannula [26, 47].
5.6 CFD Model Mesh
Following the creation of the fluid domain in CAD software, it was transferred into the
CFD package, and meshed using the models found in Table 11. The surface remesher model was
able to be used since the CAD domain generated was designed with no intersection surfaces or
other difficult geometric features that would not mesh well. Prism layers were also necessary to
have as a mesh model, since the muscular and dermis face in the model would act as a wall, and
therefore there would be a boundary layer developed on each in the model. Prism layers would be
needed to capture this detail near to these faces. The trimmer model was not as apparent as the
other mesh models given that computational limitations played a large factor in the mesh
optimization of the developed CFD model. This therefore required some more meshing trials of
the domain to reach the conclusion that the trimmer model was the best selection to create a mesh
for the adipose tissue domain model.
Table 11. Mesh models for the CFD model.
Mesh Models
Surface remesher
Prism layer mesher
Trimmer
In starting to understand the meshing trials, it must first be mentioned that the maximum
volume element count that was found to effectively run with the computational power available
was twenty-million elements. Any larger mesh than this would take significantly more time to run,
cause server errors, and did not significantly improve the residual error of the models being trialed.
The approach therefore to determining whether the tetrahedral, polyhedral, or trimmer mesh model
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was the best for the model was based around comparing the generated volume meshes by
appearance as well as the number of volume elements within the mesh. This comparison was used
since the micro sized features in the presented model require a fine mesh refinement, but based on
the computational resources available, the volume mesh cannot surpass about twenty-million
volume elements. It can be seen in Figures 24 to 26 what the results for each of these meshes was
in the proposed adipose tissue CFD fluid flow model.
The meshes all shown in Figures 24 to 26 have very similar mesh densities, but there are
very big differences in the meshes themselves. Using the tetrahedral mesh model, the overall mesh
density of the model looked good, but when inspecting the area around the capillaries, the mesh
was not acceptable as the capillary diameter was not round but rather a polygon shape due to not
enough fine mesh detail in that area. Further contributing to this, the volume mesh generated had
230-million volume elements, which was ten times more than the finest mesh found to run with
resources available. This volume mesh element count was after a redistribution of the mesh was
attempted to reduce the mesh element number as well as gain even better mesh density around the

Figure 24. Volume mesh generated using the tetrahedral mesh model on the tissue domain.
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Figure 25. Volume mesh generated using the polyhedral mesh model on the tissue domain.

Figure 26. Volume mesh generated using the trimmer mesh model on the tissue domain.
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capillaries. The polyhedral mesh model produced similar results to the tetrahedral mesh. The mesh
density looked good on the overall domain, but the mesh size around the capillaries left a polygon
shaped capillary rather than a round capillary shape. An attempt to redistribute this mesh was also
made, but the new mesh still generated a forty-million volume element mesh, which was two times
larger than was found able to run with the computational resources available. The trimmer model
on the other hand generated a volume mesh that was around twenty-million volume elements when
refined. Further, as shown in Figure 26, the capillary was a round shape with a very good mesh
density and growth rate spreading out from the capillary. This made the trimmer meshing model
the most efficient choice for the presented CFD model.
Therefore, based on the trimmer model being used on the proposed CFD model domain,
the settings identified for use in the CFD model are shown in Table 12. As previously mentioned,
these settings were identified based on knowing the computational power limits available and
using that to distribute the mesh as best as possible to areas of most interest for the developed CFD
models. This included around the capillaries and the end of the infusion set cannula. An addition
feature to the mesh was created to further improve the resolution of flow around the end of the
cannula which was a volume meshing constraint. A cylinder was created in each CFD simulation
Table 12. Mesh parameters for the CFD model.
Parameter

Value

Base Size (m)

0.1

Maximum Cell Size (% Base)

15.0

Number of Prism Layers

12

Prism Layer Stretching

1.4

Prism Layer Thickness (% Base)

0.375

Surface Curvature (#pts/circle)

100

Surface Growth Rate

1.3

Relative Minimum Size (% Base)

0.0325

Relative Target Size (% Base)

0.4

Template Growth Rate

Medium
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domain with its length axis was parallel to cannula axis, with a length of 3 mm in each direction
and a diameter of 6 mm, which was based on the rough size of the insulin depot in preliminary
trials of the domain. This volume was then refined to have a mesh size of 0.0325% relative to the
base size within its entire volume. The parameters described together generated meshes for the
case simulations previously described with the characteristic ranges as shown in Table 13. Further,
visual examples of the mesh details for one domain can be found in Figures 27 to 30.
Table 13. Mesh element ranges across the CFD simulation adipose tissue domains.
Parameter

Value

Minimum Vertices

22,712,356

Maximum Vertices

31,961,398

Minimum Face Elements

60,375,690

Maximum Face Elements

85,544,570

Minimum Volume Elements

19,697,903

Maximum Volume Elements

27,769,262

It can be seen in Figure 27 that the surface mesh shows very good resolution of the round
capillaries as well as the cannula. This can also be seen in Figure 28 where the volume mesh
generated can be seen. The volume mesh growth rate shown is acceptable given the computational
power available and refinement of the mesh needed around the small feature capillaries and
cannula in the domain. Figure 29 also shows the volume mesh was acceptable for the model on
the inner faces as well looking at the overall mesh growth as well as the details. It can be seen the
mesh was very refined around both the capillaries throughout the entire domain as well as around
the cannula. The mesh settings presented could be concluded to generate a mesh acceptable for
both the computational power available as well as the detail needed for the given model to study
the insulin deposition and dispersion related to cannula geometry and tissue thickness.
Further, the mesh resulted in acceptable error residuals and convergence, such as shown
Appendix C for each of the case simulations. The residuals for each of the cases was well below
the acceptable convergence values of in the range of 10-3 to 10-4 for complicated CFD scenarios
[61, 82]. The case models all converged on the order of 10-5 or lower. The convergence of each of
the case models also was a very smooth curve, apart from a few models with some residual
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bouncing observed during convergence. The residual errors and convergence observed was very
good considering the micro scale of the flow model as well as the meshing limitations based on
computational capacity.
Also, the mesh was developed using mesh sensitivity analysis methods. It was found from
different meshing parameters with the deposition size measured in the model simulations. It was
found at the mesh model size presented; the mesh had become an independent factor in the
simulations. This was shown by increasing and decreasing the mesh by an overall size of 5% in a
trial simulation case and observing that the insulin deposition size simulated did not significantly
change. This indicated that the mesh was not a factor impacting the results of the cases, and
therefore the was not of significant impact in the study. Further, this was shown by also considering
factors such as the velocities vectors and gradients observed across the domain as well. There was
not an observable difference in each of these results between the different mesh cases, indicating
the mesh was an independent factor within the study cases.

Figure 27. Surface mesh on round adipose domain using presented mesh settings.
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Figure 28. Volume mesh on perimeter of round adipose domain using presented mesh settings.

Figure 29. Volume mesh on inner surfaces of round adipose domain using presented mesh
settings.
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Figure 30. Cannula outlet volume element mesh constraint detail.
There were several models that were remeshed with a lower relative minimum size of
0.0324-0.0322 to obtain similar residuals to the other models. It was found that the generated mesh
in these models cause error that did not allow for good convergence, which changing the relative
minimum size was used to remediate this lack of convergence. The cases requiring this can be
found in Appendix B Table B-1. Considering these slightly more refined meshes still attained
similar residuals errors compared to the other models, the sensitivity level of the mesh was further
confirmed and proved the mesh was an independent factor in the study.
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6. Model Validation
Before meaningful results could be obtained in the study, the CFD model that was
developed had to be validated against the previously published insulin depot characteristics and
measurements, as shown by Leuenberger Jockel et al. (2013) and Zedelmair (2016), to ensure it
was an accurate model. This was able to be completed using an insulin delivery rate of 12 IU/min
and 90° x 8 mm long cannula to match previous ex vivo and CFD studies completed about insulin
delivery [26, 46]. Further, the validation was done using a simplified time dependent unsteady
CFD case as well as a complete steady state case as being considered in the current study. The
results obtained through this initial step of the study indicated the model was adequate for the study
of insulin delivery and the effect of cannula geometry and tissue thickness on its deposition and
dispersion.
6.1 Unsteady Domain Definition
As previously mentioned, a time dependent, implicit unsteady case was developed for the
validation of the presented CFD model of this study using previously published ex vivo depot
formation results. A simplified domain had to be created that did not include capillaries and
assumed symmetry across the z-axis intersecting the vertical center axis of the cylindrical domain.
Attempts were made to utilize the complete developed model domain and CFD setup from this
study in an implicit unsteady manner, with a 13.9 mm tissue thickness, as defined by the previous
studies, but this was proven to be inefficient. With the time step size required to produce accurate
results and the computational power available, in three weeks of continuous running at time of
only 0.75 seconds was able to be simulated within the CFD model. Ten seconds was required to
be simulated to reach the 2 IU threshold as done by the ex vivo study of Leuenberger Jockel et al.
(2013), and therefore a simplified domain model had to be utilized to simulate this 2 IU delivery
over ten seconds.
The domain for the unsteady case was created the same size as domain models used for the
current study, which was a 120 mm cylinder, but did not include the capillary models. The
capillaries were not a required element for this component of the current study, as they would have
little effect on the insulin depot development in the adipose tissue over the course of only ten
seconds [26]. Further, since no capillaries were present in the domain, a plane of symmetry could
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be identified in the z-direction that intersected the central axis of the cylindrical domain and
cannula. The resulting domain for this time dependent simulation is shown in Figure 31.

Figure 31. Time dependent validation case domain.
6.2 Unsteady CFD Model Conditions
The model conditions had to be altered in several respects to accommodate the unsteady
solution compared to the physics and boundary conditions set forth in the previous chapter. First,
the boundary conditions of the validation domain were a simplified set, as shown in Table 14
below.
Table 14. Boundary condition for unsteady adipose CFD model.
Domain Face

Condition

Outer Face

Pressure Outlet

Top and Bottom

Wall

Cannula Wall

Wall

Cannula Outlet Face

Mass Flow Inlet (average velocity inlet)

Vertical Mid-plane

Symmetry Plane
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The boundary conditions are the same but exclude the capillary groups and instead have
the addition of the symmetry plane across the middle of the cylindrical domain. This plane can be
seen in blue in Figure 31 above respectively. Further, the mesh relative minimum size was made
slightly larger, therefore reducing the volume elements used and the overall computational load of
each iteration of the validation model. This change in the relative minimum volume element size
as well as the total volume element count for this time-dependent domain developed can be seen
in Table 15.
Table 15. Implicit unsteady validation case meshing parameter change and mesh result.
Parameter

Value

Relative Minimum Size (% Base)

0.05

Model Domain Volume Element Count

4,142,155

The mesh generated for this validation case domain was acceptable for the use of the
domain as it still developed residual errors on the same order of the study models. The mesh can
be seen in the additional figures Appendix B and the residual error plot can be found in Appendix
C respectively. It should be noted that the cylindrical volume around the end of the cannula was
also changed in size to be a diameter of 12 mm, to be past the the insulin deposition outreach
expected in the ten second trial. Also, this volume element constraint was set to a relative volume
element size of 0.05% of the base size matching the relative minimum size of the meshing
parameters.
The model physics also had to be adjusted from a steady state solution to an implicit
unsteady state solution. This change in physics can be noted in Figure 32. It can be compared with
Figure 23 to see the only change to the physics was in in fact making the simulation an implicit
unsteady case.
Given the model being unsteady, further conditions had to be set to in the model to ensure
convergence and a valid simulation result. These included the implicit time step and maximum
inner iterations for each time step, as shown in Table 16. These parameters were set based upon
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Figure 32. Unsteady validation case model physics.
trials of the model to ensure convergence of the result and maintaining a maximum Courant
number of less than or equal to 1. This ensured that within one time step no fluid particles flowed
across more than one volume element in the case of this fluid flow in porous media model, and
therefore would cause no additional error in the model [61].
Table 16. Implicit unsteady solution parameter for time dependent adipose CFD model.
Parameter

Value

Implicit Time Step (sec)

0.001

Maximum Inner Iterations

5

6.3 Validation Results
The results from the validation compared in a 2-D planar representation of the insulin depot
in the adipose tissue subcutaneous space. The reported results by the study of both Leuenberger
Jockel et al. (2013) and Zedelmair (2016) were graphical measurement of the outreach of the
insulin deposit from the cannula center. Note that the outreach of the depot was the measurement
from the center of the cannula to the outermost edge of the insulin deposition area. Considering
this, the reported outreach and height for both the 2 IU bolus as well as a 15 IU bolus from the
cannula from those studies are found in Table 17.
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Table 17. Previously published insulin depot measurement by pump therapy.
Measurement

Value

2 IU Depot Outreach Average (mm)

5 [26]

2 IU Depot Height Average (mm)

2 [26]

15 IU Depot Outreach Average (mm)

7 [26]

15 IU Depot Height Average (mm)

7 [26]

15 IU Depot Outreach Average (mm)

8.5 [46]

15 IU Depot Height Average (mm)

8 [46]

The results from the current validation case of the presented CFD model were found by
analysis of the simulated graphical results yielded by using the case parameters of the previously
published studies [26, 46]. Considering the implicit unsteady case first, the magnitude of the
velocity was used to graphically show what the insulin depo shape would look like. This was a
valid consideration, as the interstitial fluid in the domain was assumed to be stagnant, and therefore
would have no velocity except for in the area affected by the outflow of insulin from the cannula
tip. Based on this, the area in which a velocity magnitude greater than 0 m/s could be observed
was used for the measurement of the outreach and height of the insulin depot. The area is shown
in the entire implicit unsteady domain in the additional figures of Appendix B as well as zoomed
in in Figure 33.

Figure 33. Implicit unsteady validation case insulin outreach.
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Further, the steady state recreated scenario solution could be in a loose manner compared
to the 15 IU bolus published insulin depot formation previously shown. Although both the ex vivo
and previously published CFD studies were completed in the unsteady time dependent domain
under the assumption the 15 IU bolus represents a large insulin bolus, that could be viewed as a
semi-continuous infusion. Since a steady state solution of the presented CFD model would be
representative of the average drug delivery it could be roughly correlated to the unsteady 15 IU
bolus depot results published [26, 46]. Considering this, it was assumed the dense higher-pressure
region around the cannula outlet in the steady state solution would be representative of the insulin
depot, and the pressure gradients outside of that point indicate the insulin dispersing out into the
surrounding tissue, as has been observed in previous studies considering injection pens over short
periods of time [25]. This region from the steady state solution of the validation case can be found
marked in Figure B-6 of Appendix B. It can further be seen in Figure 34 below where it is clearly
seen as the aqua blue elliptical region around the cannula tip. Further, Figure 35 indicates how this
region was measured to estimate the deposition outreach and height. It can be noted the white areas
shown in the figure are areas of pressure higher than the scale shows. The scale of the figures was
set to give better resolution of the boundaries of the insulin depot, which resulted in this clipping
of the graphical region closest to the cannula.

Figure 34. Steady state solution insulin injection depot by pressure distribution.
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Figure 35. Insulin depot by pressure distribution size definition.
The resulting measured outreach and height of the insulin depot from the developed CFD
model for the current study are shown in Table 18. In comparing these results with those of the
previously published ex vivo and CFD insulin depot formation results of Leuenberger Jockel et al.
(2013) and Zedelmair (2016) found in Table 17, it can clearly be seen that the CFD model
developed for the current study could be concluded to produce accurate results.
Table 18. Validation case insulin depot size measurements.
Measurement

Value

2 IU Depot Outreach (mm)

5.2

2 IU Depot Height (mm)

2.8

Steady State Depot Outreach (mm)

7.3

Steady State Depot Height (mm)

6.3

Considering the 2 IU bolus, the implicit unsteady case solution for the presented model
falls within 0.2 mm of the average depot outreach previously published. The height was found to
have a larger deviation of 0.8 mm though. This agreement with the previously published ex vivo
insulin deposition results provides significant validity that the model developed for the current
study provides an accurate representation of insulin deposition within the subcutaneous adipose
tissue subspace. Further emphasizing this from the previous research, the previous ex vivo study
of insulin pump infusion noted that the results were quite variable within each of the samples
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tested, and this was shown by the interquartile range for the outreach ranging from 3.7 mm to 7
mm [26].
In the case of the steady state solution, which followed the exact model parameters used in
twenty-five cases being analyzed in the current study, a good agreement was observed between
the 15 IU bolus results and this steady state insulin depot representation. The outreach interquartile
range previously presented for the 15 IU bolus was 5 mm to 13.8 mm [26]. The steady state
solution estimation of the insulin depot by the developed CFD model resulted in an insulin
outreach of 7.3 mm, which is well within the previously published ex vivo range for a 15 IU bolus,
as well as the insulin depot size previously reported by the CFD insulin depot study [26, 46]. The
height of the deposition area was also within reason compared to the previously published ex vivo
result of 7 mm and 8 mm.
Therefore, from these comparisons between the CFD model developed for the current study
and the previously published insulin deposition studies, it could be concluded the CFD model
developed for the current insulin delivery research was a valid representation for insulin infusion
into adipose tissue. This was also founded within the fact the current study scope was to consider
overall trends of insulin delivery and how the cannula geometry and tissue thickness might affect
this delivery. The agreement of the developed model indicates that the analysis of insulin delivery
trends obtained through the cases and case sets of this study are accurate and valid results.
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7. Cannula Outlet Flow
The flow directly out of the cannula would have a direct impact on the development of an
insulin depot within the adipose tissue subcutaneous space. Therefore, the first consideration of
the study was analyzing the velocity and flow pattern coming from the cannula outlet. It can be
noted that although the cannula was not modeled for the flow to develop within it, that is the
cannula outlet was an averaged outlet, for the purpose of this study comparing general trends that
was acceptable. The trends and velocities of each of the case sets, based on the cannula geometry,
were considered independently, as well as comparing and contrasting the patterns across the
different cannula geometry case sets.
7.1 90° x 8 mm Lg. Cannula
The outflow from the cannula into the adipose tissue region with a cannula geometry of
90° x 8 mm long resulted in a very symmetric velocity and flow pattern. It was found that no matter
the tissue thickness, the outflow of drug at the end of the cannula yielded no discernable difference
between the other tissue domains being tested. Further, it can be seen in the example Figure 36 as
well as the addition figures in Appendix D that the flow pattern out of the cannula was circular in
the transverse direction and semi-circular in the side profile.
It can be seen the velocity from the outlet reduces greatly in the y-direction, as would be
expected due to the anisotropic property of the tissue due to the extracellular matrix, while the
fluid decelerated slower in the x and z directions.
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(a)

(b)
Figure 36. Outflow pattern and velocity at cannula outlet in 6 mm tissue with 90° x 8 mm Lg.
cannula geometry (a) isometric view (b) side view.
7.2 45° x 13 mm Lg. Cannula
The outflow from the cannula tip with the cannula insertion angle of 45° and a length of
13 mm resulted in an elliptical velocity pattern viewed normal to the cannula end with its major
axis in the z-direction of the domain, as shown in Figure 37 and the additional figures in Appendix
D. Due to the anisotropic properties of the an insulin infusion domain, the path of least resistance
for the flow to develop was in the x-z plane, which resulted in this elliptical velocity pattern for an
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insertion angle at 45°. It can also be noted that this continues with respect to the side view of the
cannula, with drastic direction changes of the fluid exiting the bottom of the cannula and turning
back in the negative x-direction of the domain. Similarly, it was observed that the higher velocity
density exiting the cannula was in the upper region of the cannula outlet, where the fluid could exit
parallel to the x-z plane.
It was also observed that the 6 mm adipose tissue results varied from that of the thicker
tissue domains. This difference was seen in the fluid flow at the lower edge of the cannula, as seen
in comparing Figures 37 and 38, where the 6 mm tissue has a much greater fluid path found in the
negative x-direction than the thicker counterparts with the same cannula geometry. The
phenomenon could likely be attributed to the proximity of the outlet of this cannula geometry
outlet to the muscular boundary in the 6 mm adipose tissue domain.

(a)
Figure 37. Outflow pattern and velocity at cannula outlet in 6 mm tissue with 45° x 13 mm Lg.
cannula geometry (a) isometric view.
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(b)
Figure 37 cont. Outflow pattern and velocity at cannula outlet in 6 mm tissue with 45° x 13 mm
Lg. cannula geometry (b) side view.

(a)
Figure 38. Outflow pattern and velocity at cannula outlet in 12 mm tissue with 45° x 13 mm Lg.
cannula geometry (a) isometric view.
96

(b)
Figure 38 cont. Outflow pattern and velocity at cannula outlet in 12 mm tissue with 45° x 13 mm
Lg. cannula geometry (b) side view.
7.3 30° x 13 mm Lg. Cannula
The outflow from the cannula tip with the cannula insertion angle of 30° and a length of
13 mm also resulted in an elliptical velocity pattern viewed normal to the cannula end with its
major axis in the z-direction of the domain, as shown in Figure 39 and the additional figures in
Appendix D. It was observed that a high density of flow was in the z-direction and x-direction, as
shown by highest density of flow and highest velocities out in the z-directions from the sides and
in the positive x-direction. This was especially evident looking at the high velocity region skewed
toward the top of the cannula where the fluid has minimal flow bending to maintain an x-direction
flow. It was also noted that the 6 mm tissue model had a slightly lower fluid velocity at the
peripherals of the flow region compared to the other domains.
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(a)

(b)
Figure 39. Outflow pattern and velocity at cannula outlet in 6 mm tissue with 30° x 13 mm Lg.
cannula geometry (a) isometric view (b) side view.
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7.4 20° x 13 mm Lg. Cannula
The cannula geometry with an insertion angle of 20° and a length of 13 mm again yielded
an elliptical velocity pattern viewed normal to the cannula end with its major axis in the z-direction
of the domain, as shown in Figure 40 and the additional figures in Appendix D. The highest flow
density was overserved going out toward the side of the cannula as well as forward from the
cannula end in the x-direction. There was very little flow observed to proceed around the bottom
edge of the cannula. The largest portion of the flow was in the x and z directions and indicated by
the velocity density and flow streams. There was no noticeable difference in the cannula outlet
flow between the different adipose tissue domains for this cannula geometry.

(a)
Figure 40. Outflow pattern and velocity at cannula outlet in 6 mm tissue with 20° x 13 mm Lg.
cannula geometry (a) isometric view.
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(b)
Figure 40 cont. Outflow pattern and velocity at cannula outlet in 6 mm tissue with 20° x 13 mm
Lg. cannula geometry (b) side view.
7.5 20° x 17 mm Lg. Cannula
The cannula geometry with an insertion angle of 20° and a length of 17 mm, as shown by
Figure 41 and the additional figures in Appendix D, again produced an elliptical velocity pattern
viewed normal to the cannula end with its major axis in the z-direction of the domain. The highest
flow density was overserved going out toward the side of the cannula as well as forward from the
cannula end in the x-direction. There was very little flow observed to proceed around the bottom
edge of the cannula and change direction. The largest portion of the flow was in the x and z
directions and indicated by the velocity density and flow streams. There was no noticeable
difference in the cannula outlet flow between the different adipose tissue domains for this cannula
geometry.
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(a)

(b)
Figure 41. Outflow pattern and velocity at cannula outlet in 6 mm tissue with 20° x 17 mm Lg.
cannula geometry (a) isometric view (b) side view.
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7.6 Cross Case Set Analysis
Considering the insulin flow development just after leaving the cannula outlet, the flow as
generally very similar across each of the cannula geometries and tissue thicknesses. The largest
difference between the case sets was the 90° insertion angle cannula produced a much more
rotationally symmetric flow pattern than the other cannula geometries, which were much more
elliptical with a major axis in the z-direction.
Also, the velocity density pattern was much different in the lower insertion angle cannulas
than the 90° cannula, which has a very even velocity distribution across the region after the insulin
exited the cannula. The lower insertion angles on the other hand had a much greater density toward
the region leaving near the top of the cannula. This high velocity distribution was noted to move
toward the center of the cannula outlet region as the angle decreased from 45° to 20° though as
shown by comparing the side view in Figure 38, 39 and 40 respectively. It was also observed there
was no distinguishable difference created in the flow profile or velocity distribution by the cannula
with a 20° insertion angle being of length 13 mm versus 17 mm. Further detailed analysis of these
results obtained from the developed CFD model can be found in Chapter 10.
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8. Drug Deposit Formation
The formation of the insulin drug deposit in the adipose tissue could be shown in the CFD
model by examining the pressure gradients found withing the adipose tissue domain, as was done
for the steady state validation case previously discussed in Chapter 6. A two-dimensional view of
the pressure gradients was used to determine whether the cannula geometry and/or tissue thickness
were significant factors in influencing the overall length and height of this drug deposit. Using
both the graphic observations as well as statistical analysis the predicted drug deposition across
the twenty-five cases considered were able to be analyzed and compared in regard to the insulin
depot formed during delivery.
8.1 Control Cases: No Insulin Infusion
A control case for each of the tissue domains was simulated where no insulin injection
through the cannula was present into the tissue. This indicated there were no anomalies present in
any of the domains, especially in relation to the location of the cannula outlet, as shown by Figure
42, as well as the additional cases found in Appendix E.

Figure 42. 6 mm tissue thickness CFD pressure gradient with no insulin delivery.
The planar graphic of the pressure is shown using the same scale found in the later
deposition figures. It can be noted in Figure 42 that there were not any drastic pressure gradients
around the cannula end or elsewhere in the domain plane shown. Therefore, from these control
cases it was able to be concluded that the overall pressure gradients around the deposit area were
due to only direct results of insulin injection being simulated in the environment and the domain
factors that affect the overall deposition of the drug.
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8.2 90° x 8 mm Lg. Cannula
Considering the insulin infusion deposition formation with a cannula insertion angle of 90°
and cannula length of 8 mm, the deposition area was observed as represented in Figures 43 and
44. The additional tissue domain results are shown in Appendix E.

Figure 43. 6 mm tissue thickness CFD pressure gradient with 90° cannula.

Figure 44. 12 mm tissue thickness CFD pressure gradient with 90° cannula.
The largest difference observed in considering the insulin deposition shape was between
the 6 mm tissue and the other tissue thicknesses. The 12 mm, 18 mm, 24 mm, and 30 mm tissues
did not have any significant difference that could be observed between them. In regards to
comparing these depots with the 6 mm tissue though, there was a drastic difference in deposition
size. It can be seen in Figure 43 that the deposition area was over three times larger transversly
and two times taller than the other tissue thickness depots. The deposition area in the 6 mm tissue
was also only half the elliptical shape observed in the other tissue thicknesses.
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8.3 45° x 13 mm Lg. Cannula
The cannula geometry consisting of an insertion angle of 45° and cannula length of 13 mm
yield insulin deposits as represented in Figures 45 and 46. The additional tissue domain insulin
depot results are shown in Appendix E.

Figure 45. 6 mm tissue thickness CFD pressure gradient with 45° cannula.

Figure 46. 12 mm tissue thickness CFD pressure gradient with 45° cannula.
Just as was observed in the previous case set, the only noticeable difference in the insulin
deposits in the simulations of set 2 was between the depot of the 6 mm tissue compared to the
other tissue thicknesses. The depot in the 6 mm thick adipose tissue was again noted to be over
three times larger in the transverse direction and two times larger in height than the depots found
in the thicker adipose tissue domains. Also, only about half of the elliptical depot shape was
observed again in the 6 mm tissue domain.
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8.4 30° x 13 mm Lg. Cannula
The resulting insulin depot formed from infusion through a 13 mm long cannula inserted
at 30° are represented in Figures 47 and 48. The addition insulin depot formation results for this
case set can be found in the additional figures of Appendix E.

Figure 47. 6 mm tissue thickness CFD pressure gradient with 30° cannula.

Figure 48. 12 mm tissue thickness CFD pressure gradient with 30° cannula.
Again, as in the previous cases, the only noticeable difference in the insulin depots formed
during the insulin delivery through a 13 mm cannula inserted at 30° was between the depot of the
6 mm tissue compared to the thicker tissue domains. The depot in the 6 mm thick adipose tissue
was just under three times larger in the transverse and height directions than the depots found in
the thicker adipose tissue domains. The majority of the elliptical depot shape was observed in the
6 mm tissue domain with the 30° cannula insertion angle.
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8.5 20° x 13 mm Lg. Cannula
The cannula geometry consisting of an insertion angle of 20° and cannula length of 13 mm
resulted in insulin deposits as represented by Figures 49 and 50. The additional tissue domain
insulin depot results are found in Appendix E.

Figure 49. 6 mm tissue thickness CFD pressure gradient with 20° x 13 mm Lg. cannula.

Figure 50. 12 mm tissue thickness CFD pressure gradient with 20° x 13 mm Lg. cannula.
As previously observed, the only noticeable difference in the insulin deposits after delivery
through a 20° x 13 mm long cannula was between the depot of the 6 mm tissue compared to the
thicker tissue domains. The depot in the 6 mm thick adipose tissue was just over 2.5 times larger
in the transverse and height directions than the depots found in the thicker adipose tissue domains.
The majority of the elliptical depot shape was observed in the 6 mm tissue domain, with the absent
portion of the shape being at the dermis boundary of the domain rather that the muscular boundary.
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8.6 20° x 17 mm Lg. Cannula
The resulting insulin depot formed from infusion through a 17 mm long cannula inserted
at 20° are represented in Figures 51 and 52. The addition insulin depot formation results for the
rest of the tissue domains in this case set can be found in Appendix E.

Figure 51. 6 mm tissue thickness CFD pressure gradient with 20° x 17 mm Lg. cannula.

Figure 52. 12 mm tissue thickness CFD pressure gradient with 20° x 17 mm Lg. cannula.
Finally, the only noticeable difference in the insulin deposits formed after infusion through
a 20° x 17 mm long cannula was between the depot of the 6 mm adipose tissue model compared
to the thicker tissue domains. The depot in the 6 mm thick adipose tissue was again over 2.5 times
larger in the transverse and height directions than the depots found in the thicker adipose tissue
domains. The majority of the elliptical depot shape was observed in the 6 mm tissue domain, with
the depot being about centered in the height of the tissue domain.
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8.7 Cross Case Set Analysis
There were differences observed in each of the sets between the 6 mm tissue insulin depots
and the depots in the thicker tissue domains. This trend can be more clearly seen in the insulin
deposit radial length and height measurements across each of the case sets and tissue thicknesses
as found in Figure 53 and 54. The depot shape being measured for each of the cases can be seen
in Appendix E. It can be noted the insulin depot was measured in the same manner as the steady
state validation case, as shown in Figure 35. It was clearly seen that the 6 mm tissue sample results
in a much larger deposit of insulin in both length and height compared to the other tissue thickness
in each of the case sets.

Figure 53. Insulin depot radial length vs. cannula geometry and tissue thickness.
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Figure 54. Insulin depot height vs. cannula geometry and tissue thickness.
What was noted when looking at how the different case set compare to each other though
was that overall, in the case of the 6 mm adipose tissue domains, the length of the depot trended
downward across the sample sets, while the height trended upward. In the thicker tissue samples,
the insulin deposition length and height stayed relatively constant across the case sets, with a
notable increase in both dimensions only in the case of a cannula geometry of length 13 mm and
insertion angle of 20° respectively.
To further quantify these results, a two-factor analysis of variance (ANOVA) statistical
analysis was completed for both the length and height measurements of the simulated insulin
depots for each case. Assuming a significance level of 0.05, it was shown that across all of the case
sets and tissue thicknesses, the tissue thickness was a factor of significance, while the cannula
geometry was not of significance in the insulin depot measurements, as shown by the P-values of
the analysis found in Table 19.
Given the difference that was able to be seen between 6 mm tissue thickness and thicker
tissue domain depot results in each of the case sets, a single factor ANOVA was completed on the
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6 mm tissue cases considering each of the five cannula geometries considered for both the length
and height of the insulin depot. This was done in order to examine whether the cannula geometry
Table 19. Two-factor ANOVA without replication results.
Factor

Deposition Length P-value

Deposition Height P-value

Cannula Geometry

0.602

0.0535

Tissue Thickness

4.677 ´ 10-14

1.0267 ´ 10-10

was a significant factor across the thin 6 mm tissue on its own. It was found that the cannula
geometry was significant in both the case of the length and height of the insulin deposit, as shown
by the P-values in Table 20 below.
Table 20. One-factor ANOVA without replication results for 6 mm tissue thickness.
Factor

Deposition Length P-value

Deposition Height P-value

Cannula Geometry

1.095 ´ 10-6

0.0234

Similarly, a two-factor ANOVA was completed for all of the length and height
measurements excluding the 6 mm tissue simulations. This isolated the more similar thick tissue
depot formations to analyze the significant factors in this similar grouping. The ANOVA, as shown
in Table 21, indicated that when considering the depot results without the 6 mm samples, both the
cannula geometries and tissue thicknesses were significant factors for both the length and height
of the insulin depot.
Table 21. Two-factor ANOVA without replication results excluding 6 mm tissue thickness.
Factor

Deposition Length P-value

Deposition Height P-value

Cannula Geometry

6.891 ´ 10-8

1.626 ´ 10-6

Tissue Thickness

8.252 ´ 10-12

5.953 ´ 10-9

Further, looking at just the two sets of cases using the 20° insertion angle with an either 13
mm or 20 mm cannula, it was found that there was not statistical significance between these two
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case sets across the different tissue thicknesses. This was done using a t-test assuming unequal
variance with a significance level of 0.05, which resulted in the P-values as shown below in Table
22.
Table 22. T-test assuming unequal variance for 20° insertion angle cannula with different
cannula lengths.
Factor

P-value (one-tail)

P-value (two-tail)

Cannula Length

0.42163093

0.84326185

Even with the small sample sizes, which could be accounted for assuming unequal
variance, the P-value was found to be much higher than the confidence level of 0.05, and therefore
the hypothesis that there was no difference between the mean values of the two data sets was
upheld. This indicated therefore that there was not a statistically significant difference in the
deposition of insulin due the depth the cannula was placed into the adipose tissue domain at a 20°
insertion angle. Further detailed analysis of these results obtained from the developed CFD model
can be found in Chapter 10.
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9. Average Drug Dispersion Pattern
A large component of the drug delivery in adipose tissue is the drug flow away from the
cannula after deposition. The manner in which the largest density of the drug flows away from
depot and the direction in which it does could largely be affected by the cannula geometry, tissue
thickness, as well as tissue vascularization. This dispersion plays directly into drug uptake from
the adipose tissue extracellular space. Therefore, simulating the flow pattern away from the
cannula outlet in the steady state model through the use of streamlines gives a visual representation
of what this average drug dispersion would look like given the designed CFD domain.
9.1 90° x 8 mm Lg. Cannula
In the case of the CFD models with a 90° insertion angle and 8 mm long cannula, it was
shown that the overall drug dispersion pattern across the simulations was a very symmetric and
planar circular pattern. This can be seen in Figures 55 and 56 as well as the additional figures

(a)
Figure 55. Average drug dispersion from cannula for 6 mm tissue and 90° cannula (a) top view.
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(b)
Figure 55 cont. Average drug dispersion from cannula for 6 mm tissue and 90° cannula (b) side
view.

(a)
Figure 56. Average drug dispersion from cannula for 12 mm tissue and 90° cannula (a) top view.
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(b)
Figure 56 cont. Average drug dispersion from cannula for 12 mm tissue and 90° cannula (b) side
view.
in Appendix F. It can be seen that the 6 mm tissue thickness resulted in a larger diameter dispersion
outreach as well as a much more planar distribution than the thicker tissue domains. The overall
distribution in the 6 mm tissue appears to rise in the domain slightly after injection. The thicker
tissue domains also do rise slightly as the dispersion moves outward, but directly under the cannula
outlet there is noted to be dispersion downward into the tissue as well.
In comparing the thicker tissue domains, it can be seen that the 12 mm tissue thickness has
a smaller diameter outreach than the thicker adipose tissues, and the 30 mm thick tissue has the
widest outreach diameter of the thicker tissue domains.
9.2 45° x 13 mm Lg. Cannula
The observed insulin drug dispersion pattern across the models with a cannula insertion
angle of 45° and 13 mm length was a planar elliptical shape with a longitudinal axis running in the
z-direction in the 6 mm tissue thickness as shown in Figure 57 respectively. In contrast, as shown
by Figure 58 as well as the additional figures in Appendix F, there was symmetry observed across
the x-axis in the top view, but the depth dispersion differed greatly from the thinner 6 mm tissue
domain. The insulin was noted to disperse deeper into the tissue then follow a parallel path to the
muscular boundary of the domain in the case of the 12 mm and 18 mm tissue domains, while in
the 6 mm domain the dispersion went upward due to the close proximity to the muscular boundary
of the cannula outlet.
The 24 mm and 30 mm tissue domain simulations showed that the dispersion of the drug
would have a larger outreach than the 12 mm and 18 mm adipose tissue thicknesses, as well as
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(a)

(b)
Figure 57. Average drug dispersion from cannula for 6 mm tissue and 45° cannula (a) top view
(b) side view.
have a more broad and straight path dispersion into the adipose tissue. The drug dispersion was
noted to not reach a point in which the muscular layer influences the dispersion pattern to flow
parallel to the lower tissue boundary in these thicker tissue domains.

116

(a)

(b)
Figure 58. Average drug dispersion from cannula for 12 mm tissue and 45° cannula (a) top view
(b) side view.
9.3 30° x 13 mm Lg. Cannula
Considering the cases in which the cannula was inserted at 30° and had a length of 13 mm,
the observed insulin dispersion pattern across each of the tissue thickness domain was very similar.
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From the top view, it could be seen that each of dispersion patterns was semi elliptical in shape
with its major axis in the z-direction, as shown by Figure 59 and 60 as well as the additional figures
in Appendix F.

(a)

(b)
Figure 59. Average drug dispersion from cannula for 6 mm tissue and 30° cannula (a) top view
(b) side view.

118

(a)

(b)
Figure 60. Average drug dispersion from cannula for 12 mm tissue and 30° cannula (a) top view
(b) side view.
In the side view, the x-y plane the dispersion pattern was very similar in each of the tissue thickness
domains also. The 6 mm domain did show a slight variance with a larger segment of insulin
dispersion going above the cannula outlet compared to below, but this could be attributed to the
domain thickness constraint on the dispersion, as seen in Figure 59. A smaller planer area of
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dispersion was also observed in the 6 mm tissue domain compared to the thicker adipose tissue
models, as shown in the top views of the figures above.
9.4 20° x 13 mm Lg. Cannula
The modeled insulin dispersion after delivery through a 20° x 13 mm long cannula matched
each other even more closely across the five tissue domains than previous case sets. It can be seen
in Figure 60, 62, and the additional figures in Appendix F that the insulin dispersion pattern in the
transverse plane was not notably different from one tissue domain to the next. A semi-elliptical
dispersion pattern was again noticed in the top view with a longitudinal axis in the z-direction. The
side profile of the dispersion pattern also had a circular shape to it and extends toward both the
upper dermis layer and the lower muscular layer of the domain in each of the tissue thicknesses.

(a)
Figure 61. Average drug dispersion from cannula for 6 mm tissue and 20° x 13 mm Lg. cannula
(a) top view.
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(b)
Figure 61 cont. Average drug dispersion from cannula for 6 mm tissue and 20° x 13 mm Lg.
cannula (b) side view.

(a)
Figure 62. Average drug dispersion from cannula for 12 mm tissue and 20° x 13 mm Lg. cannula
(a) top view.

121

(b)
Figure 62 cont. Average drug dispersion from cannula for 12 mm tissue and 20° x 13 mm Lg.
cannula (b) side view.

9.5 20° x 17 mm Lg. Cannula
The modeled insulin dispersion for the cases in which a cannula of 17 mm long and
insertion angle of 20° was used also had a very similar dispersion pattern to each other in each
tissue thickness considered. It can be seen in Figure 63, 64, and the additional figures in Appendix
F that the insulin dispersion pattern was observed to be very similar in shape with respect to the
transverse direction of the domains, with the 6 mm tissue domain having a slightly smaller
longitudinal elliptical axis length than the thicker tissue domains. the different tissue domains. The
side profile of the dispersion pattern also was very similar, with a slight variation noted in the 6
mm tissue thickness as it reached the muscular layer of the domain while the thicker adipose tissue
models were unobstructed by this boundary.
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(a)

(b)
Figure 63. Average drug dispersion from cannula for 6 mm tissue and 20° x 17 mm Lg. cannula
(a) top view (b) side view.
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(a)

(b)
Figure 64. Average drug dispersion from cannula for 12 mm tissue and 20° x 17 mm Lg. cannula
(a) top view (b) side view.
9.6 Cross Case Set Analysis
Considering the dispersion patterns observed across the five case sets of cannula
geometries, several noted insulin dispersion differences across the domains were a direct result of
the cannula geometry and the tissue thickness. First, it was generally seen that the lower the
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insertion angle of the cannula, the lower the dispersion in the x-z plane of the tissue. Adding to
this, as the insertion angle decreased the density of the flow in the x-direction of the domain
decreased as well. These dispersion trends were observed from the 45° insertion angle proceeding
down to the 20° insertion angle.
It was observed when comparing across the cannula geometry sets that the 90° and 45°
insertion angles resulted in unique insulin dispersion, but once the cannula had an insertion angle
of 30° or below, the insulin dispersion was very similar between the angles of insertion. This can
be seen by how closely the 30° and 20° insertion angle results match each other, being almost
indiscernible when compared, such as in Figures 60 and 62 respectively. The 90° insertion cannula
and 45° insertion cannula both were shown to have a more uniform distribution of insulin
dispersion around the cannula as well as greater outreach of the dispersion.
It was also noted when comparing the two cannula lengths of 13 mm and 17 mm inserted
at an angle of 20°, the 17 mm cannula was found to generate a greater insulin distribution compared
to the 13 mm cannula. This can be seen by comparing Figure 62 and 64, where the 13 mm cannula
dispersion appears to be limited by its close proximity to the dermis boundary of the adipose tissue
region. Further detailed analysis of these results obtained from the developed CFD model can be
found in Chapter 10.
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10. Research Outcome Analysis
From the observations made as the flow of insulin moves from the end for the infusion
cannula to dispersing in the tissue, there were various larger trends that were found that can be
applied to current understanding of insulin pump therapy. Further, these trends can be applied to
current insulin therapy methods to indicate what further developments could improve treatment as
well as standardize insulin delivery across the various anatomical conditions faced by patients.
10.1 Thin Adipose Tissue
The biggest observation through this study was that the constant case that had the largest
effect on the insulin delivery as well as the greatest variability from cannula geometry to cannula
geometry was the thin 6 mm adipose tissue domain. One of the notable causes of this due to the
infusion set cannula geometry was the proximity of the outlet to the muscular boundary. This was
largely displayed in the results of the 90° x 8 mm long cannula and 45° x 13 mm long cannula
delivery insulin into the 6 mm tissue domain. With the insulin being infused very close to a solid
boundary, there was little volume in the negative y-direction to be filled. Therefore, the only
volume for the insulin to disperse to after leaving the cannula was out around the point of infusion
in the x-z plane and above the point of infusion.
Throughout the study the thin adipose region was shown to affect even the flow directly
out of the cannula at the micro scale. It was also largely observed in the formation of the insulin
depot, and further by the large dispersion area of the insulin. Previous research in insulin delivery
suggested that the hydraulic pressure dictated how insulin dispersed in the transverse direction
before the interstitial pressure was great enough for the insulin to permeate the extracellular layer
[26]. The case of the 6 mm tissue domain presented an extreme example of this phenomenon with
the injection area being so close to the upper and lower boundaries of the adipose subcutaneous
space that hydraulic pressure required for fluid particle move vertically in the tissue subspace was
very large, resulting in a more transverse dispersion.
10.2 Deposition and Dispersion
In addition to the noted observations of the thin tissue domain, the same hydraulic pressure
induced distribution could be attributed as the cause for the pattern of deposition and dispersion
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noted in comparing the different cannula geometry cases. Even though the transverse direction had
a greater porosity, as the cannula insertion angle decreased, the insulin diffusion trended to
penetrate deeper into the tissue and not radiate out as much transversely. This would likely come
from the fact that although the x and z directions had a greater porosity, when the cannula was
directing insulin primarily in the positive x-direction of the domain, a greater flow resistance was
induced within the medium in this direction compared to the other directions. The localized
hydraulic pressure induced by the continuous flux of insulin in the x-direction could have resulted
in the path of least resistance for the insulin to spread in the tissue to be the positive or negative zdirection and even down in the less porous y-direction over the higher-resistant positive xdirection. This phenomenon was even observed in the flow development directly out of the cannula
end, as shown in Chapter 7. This observation would agree with previous subcutaneous infusion
research that attributed the higher transverse spread of the drug to the medium flow resistance and
porosity of the tissue around the site [26].
What should be noted here though is that although this trend was observed in this study,
this would have to be confirmed with further study in tissue porosity and permeability and how
the different cannula angles would affect ex vivo insulin deposition and dispersion. The previous
studies only considered variations of a 90° insertion angle cannula, and therefore, the modeled
directionally varied porosity of the tissue was based off these results [26, 46]. The way in which
the current study modeled the anisotropic nature of the adipose tissue due to the extracellular
matrix was most accurate manner based upon the very minimal information about this region
available. Therefore, it is unclear how a lower angled infusion cannula effects the overall
deposition and dispersion of the insulin in actual biologic adipose tissue. The observed results are
viable though by the current understanding of porous media modeling, the hydraulic nature of drug
diffusion previously observed in studies, as well as the verification of the model as discussed in
Chapter 6 [3, 5, 11, 21, 23, 25, 26, 54].
Another factor not previously discussed was the observation that in the thin tissue samples,
such as the 6 mm and often the 12 mm domain, the delivery was near the bottom or center of the
tissue depth. In the case of the thicker tissues though, this deposition area was very high in the
adipose region, especially when considering the low insertion angle cannulas. The overall
dispersion pattern was similar to thinner adipose tissue domains being considered, but there was a
drastic difference in the relative location within the tissue where the depot and dispersion fell.
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Although this did not have significance in the case of how the deposition and dispersion occurred,
this would likely have greater implications for actual insulin absorption.
10.3 Applications for Understanding Insulin Delivery
Based on these results, several applications concerning current insulin delivery dynamics
using pump therapy were able to be drawn. First, concerning insulin delivery in lean patients, it
could be concluded that the cannula geometry has a significant effect on insulin deposition and
dispersion in the adipose tissue. One indication of this would be the impact observed on the insulin
depot size as well as dispersion out into the adipose subspace when the cannula geometry was
varied in the study. As the drug requires contact with capillaries to be absorbed into the blood
stream and ultimately used by the body physiologically, the shape and size the insulin flows during
infusion would be crucial to delivery effectiveness. Therefore, applying this practically, being able
to achieve a larger volume of insulin deposition and a larger area of dispersion would ultimately
result in more effective administration of the insulin as the drug would be in contact with a greater
number of these capillaries. Further, as previously stated in published research, the longer the drug
is in the extracellular area of the adipose tissue, the higher the chance of localized factors that
impact the drug molecules and tissue itself, resulting in variable kinetics of the insulin [5, 16, 23].
A further application related insulin absorption from the current study results would be
related to the fact that thicker tissue has been found to be a less vascularly dense tissue [53].
Therefore, this would be of great significance, as the lower infusion angle cannulas produced an
almost identical diffusion pattern across each of the tissue thicknesses considered. If the thicker
tissue had a lower vascular density, as was assumed by the model, but the same diffusion of insulin
as a thinner adipose tissue sample, the kinetics of absorption for the insulin would be drastically
different between the two tissues. This would add additional significance to the fact that cannula
geometry plays a significant role in insulin deposition and dispersion. It does also facilitate that
the cannula geometry and the tissue thickness do have a dependent relationship, as was able to be
shown in the statistical metrics of the lean tissue in this study.
This application relating the dispersion characteristics of insulin due to low insertion angle
cannulas and vascularization in different thickness adipose regions could be applied to a single
patient’s anatomy also. Previous research showed that the regions of the body suitable for insulin
delivery could have varied thickness even within an individual [48-50]. Therefore, applying the
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previous discussion about the absorption in different tissue thickness related to diffusion and
vascularization, and overal insulin absorption, it could be concluded that using one cannula
geometry in different anatomical regions could result in variable insulin kinematics within a single
patient. This application is critical, because the treatment of Type 1 Diabetes relies upon the
observations of blood glucose trends over time, whether manually adjusting insulin rates or using
an autonomous system to maintain blood glucose homeostasis. The implication of this on
autonomous pump therapy would be that precise insulin requirements for even an individual
patient would not be easily achieved due to varied insulin kinematics from day to day due to
infusion site rotation. Autonomous pump systems base insulin requirements off days to even weeks
of average insulin use and the resulting blood glucose control. This indicates blood glucose
homeostatic balance would be greatly affected by varied insulin kinetics across the anatomic tissue
regions across the patient varied insulin kinetics within the adipose tissue, even when using a close
loop pump system. A further factor of this also would be that the thinner tissue and different
anatomical regions would be more likely to have dispersion affected by a “massaging” effect due
to the movement of the muscle below the adipose tissue. Based on the previous ex vivo research,
this would affect the insulin depot and dispersion causing the drug to spread farther out
transversely in the tissue, in turn being an additional factor affecting the absorption kinetics [26].
Therefore, it would be necessary to develop a system to limit absorption variable across single
patient anatomical regions, whether that be using specific cannula geometries employed in specific
regions or another method.
Finally, in relation to observation made throughout this study and the actual insulin
absorption kinetics into the capillaries, it could be concluded there may be an effect on how the
different cannula geometries and tissue thicknesses affect this physiological function. As
previously described, the interstitial fluid is always flowing, as driven by capillary exchange into
and out of the extracellular space around the adipocytes [27-35]. The exchange is facilitated
through the oncotic pressure differential between the intra-capillary region and the extracellular
adipose regions [27, 28]. Understanding this, there is a possibility that this kinetic exchange would
be affected by the pressure induced through the injection of insulin into the region that is already
saturated with fluid. Further, the combination of the different cannula geometries and tissue
thicknesses was shown to induce a different localized pressure area (noted as the insulin depot)
depending on the cannula and tissue combination, as shown Chapter 8. Therefore, further research
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to study if this localized pressure disturbance in the tissue due to insulin delivery affects this
physiologic interchange, and what implication that may have for insulin delivery would be a
warranted area of research.
Overall, the development of the CFD model of insulin delivery into the adipose region and
the results obtained through this study in conjunction with previous research indicated there is a
need for further research in this area subcutaneous drug delivery. It was shown that the cannula
design in relation to the anatomical variations of adipose tissue did produce significantly different
results, that would, even based on a simplified understanding of insulin kinetics, have a large effect
on insulin delivery in the treatment of Type 1 Diabetes. These results further validated previous
research studies that also called for an action to better understand infusion set delivery and insulin
kinetics, indicating it was one of the weak points of current pump delivery systems [8, 14, 20].
Considering autonomous insulin pumps are already used in insulin therapy, this study provided
evidence that a further understanding the delivery mechanics of insulin in relation to the pump
cannula and tissue interface should be a priority in order to improve individualized Type 1 Diabetes
management.
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11. Conclusion
Drug delivery could be said to be one of the most important components of medical
treatments, as it requires the ability to achieve the desired target response, but at the same time
reduce the possibility for any adverse ramifications. An additional component to this is the patient
quality of life during treatment, which has a large importance in chronic conditions such as Type
1 Diabetes. The current state of the art systems for insulin administration includes insulin infusion
pumps continuously into the adipose tissue between the dermis and muscular layers used in
conjunction with continuous glucose monitors to achieve a closed loop insulin infusion system for
more precise control of patient blood glucose levels by delivery the drug.
Given the importance of the nature of especially accurate and predicable drug delivery,
high variability of insulin delivery even within a single patient has been identified in research.
Influential factors such as physiologic and biologic functions, adipose tissue anatomy, and the
infusion set design have all been factors identified as creating this variability. Little research has
indicated the effect each of these factors may have on insulin delivery though. Utilization of
technology such as computational fluid dynamics (CFD) model can lead the way in the study of
these factors’ effects on the kinetics of insulin within the adipose tissue domain.
In studying previously published research in the areas around subcutaneous drug delivery,
insulin and other drug kinetics, fluid flow in biologic tissue, and other areas relating to
subcutaneous biology, it was evident there has been a large chasm between in vivo type research
and computational models when it comes to drug delivery, especially regarding insulin infusion.
The literary research indicated a CFD model could be designed to simulate the interstitial fluid
flow in adipose tissue induced by capillary exchange. Further, previously developed models
provided useful insight into modeling biological tissue as a porous medium and obtain accurate
results from this assumption about biological tissue. Additionally, other published research
provided crucial insight into the unique characteristics of adipose tissue, such as its extracellular
matrix, required to create such a model. From this research, a study using computational models
in the area of insulin delivery was able to be designed.
A porous media CFD model was able to be developed to model the adipose tissue
environment with its interstitial fluid flow induced by capillary fluid exchange within the subspace.
The anisotropic nature of the domain was modeled using previously published observations from
biologic tissue through the application of the Ergun equation. Insulin delivery was incorporated
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into the model, and its accuracy was verified using previously published ex vivo research on insulin
infusion in both a time-dependent and steady state scenario. The recreation of this published ex
vivo insulin delivery study using the developed CFD model yielded very similar results to the
original published study insulin depot.
The current study was designed to analyze the effect of both cannula geometry and tissue
thickness on the deposition and dispersion of insulin within the adipose tissue subcutaneous space.
The five most common cannula geometry currently used in pump therapy and a range of adipose
tissue thicknesses that encompasses the range from lean to obese patients were considered as the
design variables. The cannula geometry varied in insertion angle from 90° to 20° and in length
from 8 mm to 17 mm. The adipose tissue domains were the range of 6 mm to 30 mm. Each cannula
design was studied in each tissue thickness to analyze the effect of these factors on insulin
deposition and dispersion.
The results and analysis of these CFD models indicated that both the cannula geometry and
the tissue thickness have a significant influence insulin deposition and dispersion. The cannula
geometry was observed to impact the flow development directly from the cannula end. Further, in
considering the insulin depot formation in the regards to the different tissue thickness and cannula
geometries, it was found using an ANOVA two-factor statistical test, the tissue thickness and
cannula geometry were of significance, in both the case of lean and obese adipose tissue. It was
also observed that the length was not a significant factor in insulin depot development at a low
insertion angle using a statistical t-test.
In addition, through graphical comparison of the dispersion pattern of the insulin in the
adipose tissue using streamlines it was further shown that 6 mm adipose tissue thickness resulted
in a much different dispersion pattern regarding higher insertion angle cannula geometries
compared to the thicker tissue domains. It was observed for the lower insertion angles though the
dispersion pattern of the insulin infused from the cannula was very similar between the different
tissue thickness, only different according to the exact cannula design. Also, the results indicated
that the shallower angle of insertion resulted in a lower level of dispersion in x-direction as well
as a lower transverse propagation from the cannula outlet.
Therefore, through the analysis of these results coupled with the current understanding of
adipose tissue physiology and adipose drug delivery kinetics, the conclusion first could be made
that a CFD model is not only a viable way to study drug delivery, but also a valuable tool for
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studying the delivery of drugs such as insulin. Further it was observed that both the tissue thickness
and cannula design have a significant impact insulin deposition and dispersion in adipose tissue.
It was also shown that a great variation in drug kinetic would be found in lean patients because of
differing cannula designs on insulin delivery. Similarly, the results indicated a drastic difference
would be observed in insulin absorption kinetics due to the variation of vascularization in lean
versus thick adipose tissue with a low angle of infusion cannula.
Overall, the yielded results indicated that further research into the effect of two significant
factors impacting delivery, cannula geometry and tissue thickness, is warranted. This is especially
true considering new autonomous infusion pump require very predictable day to day insulin
kinetics to improve blood glucose control rather than increase risk for dangerous blood glucose
levels. Therefore, the CFD model was able to be used as a tool to better understand insulin kinetics,
but this was just a first step in the direction of understanding and simulating insulin delivery to be
able to predict individual patient kinetics. To reach such a level of individualize patient care
though, this study proved a significant amount of research in both the parameterization of
biological tissue anatomy and flow as well as further factors that influence insulin delivery must
be studied. Through this additional research, the treatment of Type 1 Diabetes, and other treatments
utilizing subcutaneous delivery could be greatly improved.
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12. Future Work
Several areas of further study were able to be indicated by the results of this study. First,
the completion of a singular case in the time dependent domain and simulate the delivery of insulin
over an entire day period. This would include at least several insulin boluses as well as a continual
basal insulin rate throughout the day. This type of study would be a first step in the direction of an
individual patient simulator model that could better be used to tailor treatment plans to patients.
This study would be also able to indicate how continuous infusion causes the infused drug
concentration to grow and shrink depending on infusion rate and bolus size.
Further, characteristic parameters of adipose tissue require more study to increase the
understanding of the biological environment and the computational modeling of such
environments. The interstitial flow, for instance, could be studied as a factor that may influence
the dispersion of the insulin within the tissue, especially in a time dependent domain. Another
parameter that could be further investigated and quantified to improve CFD modeling would be
the anisotropic effect of the adipose tissue on true biological tissue using different cannula
geometries. This would allow for the anisotropic properties of the adipose tissue that influence
insulin delivery to be more accurately modeled in the computational model domain for further
insulin deposition study.
Additionally, another element of study would be the addition of muscular motion to the
model, in order the better simulate the dynamic nature of the anatomic region the insulin is being
delivered to. This would especially hold true in tissue on the legs where the muscle is constant
motion during walking and physical activity. A study looking into this phenomenon would help to
understand the kinetics of insulin in different anatomic regions of the body due to the tissue
movement around the infusion site.
Finally, a similar CFD model or the refined CFD model could be used in the design of new
cannula geometries. It could be used as a tool to prove the deposition and dispersion pattern,
allowing for the ability to better predict the insulin deposition for ideal and consistent insulin
kinetics. This allows for a very efficient way to trial new cannula designs as well as visualize how
it may compare to another design in a very controlled tissue sample.
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Appendix A: Mathematical Calculations
Unit conversion for IU/min to kg/s:
First, noting that 100 units of insulin (IU) are in 1 mL of drug solution, therefore one IU is:
1 (f
1 cd = e
g = 0.01 (f
100 cd
Then, converting this to time dependance, the unit of IU/min converted to mL/s would be:

1

cd
1 (f
1 (0+
(f
=e
ge
g = 1.6667 × 10-S
(0+
100 cd 60 )$;
)

The density of the insulin drug solution is 1.005 g/mL [83], making the conversion from mL/s to
kg/s as follows:
1.6667 × 10-S

(f
1.005 G
1 HG
HG
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ge
g = 1.675 × 10-I
)
1 (f
1000 G
)

Therefore, 1 IU/min is 1.675 × 10-I kg/s.

135

Appendix B: Additional Model Development Figures

Figure B-1. Use case of maximum server power during case trial running (total of 64 GB of
ram).

Figure B-1. Noted stagnation velocities created by capillary exchange linearized velocities.
136

Table B-2. Model cases requiring smaller relative minimum cell size.
Relative Minimum
Case (tissue thickness /cannula geometry)
Size (% base)
18 mm/90° x 8 mm
0.3235
30 mm/90° x 8 mm
0.0324
30 mm/45° x 13 mm
0.0322
30 mm/30° x 13 mm
0.0324
18 mm/20° x 13 mm
0.0324
30 mm/20° x 17 mm
0.0323

Figure B-2. Unsteady validation case domain surface mesh.

Figure B-3. Unsteady validation case domain outer volume mesh.
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Figure B-4. Unsteady validation case domain interior volume mesh.

Figure B-5. Unsteady validation case domain interior volume mesh.
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Figure B-6. Steady state validation case showing pressure contours around cannula outlet
marking insulin depot.

Figure B-7. Steady state validation case full domain side view.
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Appendix C: Error Residuals for Cases

Figure C-1. Residuals error plot for implicit unsteady verification case.

Figure C-2. Maximum Courant number plot for implicit unsteady verification case.
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Figure C-3. Residuals error plot for steady state verification case.

Figure C-4. Residuals error plot of 6 mm tissue with 90° x 8 mm Lg. cannula.
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Figure C-5. Residuals error plot of 12 mm tissue with 90° x 8 mm Lg. cannula.

Figure C-6. Residuals error plot of 18 mm tissue with 90° x 8 mm Lg. cannula.
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Figure C-7. Residuals error plot of 24 mm tissue with 90° x 8 mm Lg. cannula.

Figure C-8. Residuals error plot of 30 mm tissue with 90° x 8 mm Lg. cannula.
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Figure C-9. Residuals error plot of 6 mm tissue with 45° x 13 mm Lg. cannula.

Figure C-10. Residuals error plot of 12 mm tissue with 45° x 13 mm Lg. cannula.
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Figure C-11. Residuals error plot of 18 mm tissue with 45° x 13 mm Lg. cannula.

Figure C-12. Residuals error plot of 24 mm tissue with 45° x 13 mm Lg. cannula.
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Figure C-13. Residuals error plot of 30 mm tissue with 45° x 13 mm Lg. cannula.

Figure C-14. Residuals error plot of 6 mm tissue with 30° x 13 mm Lg. cannula.
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Figure C-15. Residuals error plot of 12 mm tissue with 30° x 13 mm Lg. cannula.

Figure C-16. Residuals error plot of 18 mm tissue with 30° x 13 mm Lg. cannula.
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Figure C-17. Residuals error plot of 24 mm tissue with 30° x 13 mm Lg. cannula.

Figure C-18. Residuals error plot of 30 mm tissue with 30° x 13 mm Lg. cannula.
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Figure C-19. Residuals error plot of 6 mm tissue with 20° x 13 mm Lg. cannula.

Figure C-20. Residuals error plot of 12 mm tissue with 20° x 13 mm Lg. cannula.
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Figure C-21. Residuals error plot of 18 mm tissue with 20° x 13 mm Lg. cannula.

Figure C-22. Residuals error plot of 24 mm tissue with 20° x 13 mm Lg. cannula.
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Figure C-23. Residuals error plot of 30 mm tissue with 20° x 13 mm Lg. cannula.

Figure C-24. Residuals error plot of 6 mm tissue with 20° x 17 mm Lg. cannula.
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Figure C-25. Residuals error plot of 12 mm tissue with 20° x 17 mm Lg. cannula.

Figure C-26. Residuals error plot of 18 mm tissue with 20° x 17 mm Lg. cannula.
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Figure C-27. Residuals error plot of 24 mm tissue with 20° x 17 mm Lg. cannula.

Figure C-28. Residuals error plot of 30 mm tissue with 20° x 17 mm Lg. cannula.
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Appendix D: Chapter 7 Additional Figures

(a)

(b)
Figure D-1. Outflow pattern and velocity at cannula outlet in 12 mm tissue with 90° x 8 mm Lg.
cannula geometry (a) isometric view (b) side view.
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(a)

(b)
Figure D-2. Outflow pattern and velocity at cannula outlet in 18 mm tissue with 90° x 8 mm Lg.
cannula geometry (a) isometric view (b) side view.
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(a)

(b)
Figure D-3. Outflow pattern and velocity at cannula outlet in 24 mm tissue with 90° x 8 mm Lg.
cannula geometry (a) isometric view (b) side view.
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(a)

(b)
Figure D-4. Outflow pattern and velocity at cannula outlet in 30 mm tissue with 90° x 8 mm Lg.
cannula geometry (a) isometric view (b) side view.
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(a)

(b)
Figure D-5. Outflow pattern and velocity at cannula outlet in 18 mm tissue with 45° x 13 mm
Lg. cannula geometry (a) isometric view (b) side view.
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(a)

(b)
Figure D-6. Outflow pattern and velocity at cannula outlet in 24 mm tissue with 45° x 13 mm
Lg. cannula geometry (a) isometric view (b) side view.
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(a)

(b)
Figure D-7. Outflow pattern and velocity at cannula outlet in 30 mm tissue with 45° x 13 mm
Lg. cannula geometry (a) isometric view (b) side view.
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(a)

(b)
Figure D-8. Outflow pattern and velocity at cannula outlet in 12 mm tissue with 30° x 13 mm
Lg. cannula geometry (a) isometric view (b) side view.
161

(a)

(b)
Figure D-9. Outflow pattern and velocity at cannula outlet in 18 mm tissue with 30° x 13 mm
Lg. cannula geometry (a) isometric view (b) side view.
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(a)

(b)
Figure D-10. Outflow pattern and velocity at cannula outlet in 24 mm tissue with 30° x 13 mm
Lg. cannula geometry (a) isometric view (b) side view.
163

(a)

(b)
Figure D-11. Outflow pattern and velocity at cannula outlet in 30 mm tissue with 30° x 13 mm
Lg. cannula geometry (a) isometric view (b) side view.
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(a)

(b)
Figure D-12. Outflow pattern and velocity at cannula outlet in 12 mm tissue with 20° x 13 mm
Lg. cannula geometry (a) isometric view (b) side view.
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(a)

(b)
Figure D-13. Outflow pattern and velocity at cannula outlet in 18 mm tissue with 20° x 13 mm
Lg. cannula geometry (a) isometric view (b) side view.
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(a)

(b)
Figure D-14. Outflow pattern and velocity at cannula outlet in 24 mm tissue with 20° x 13 mm
Lg. cannula geometry (a) isometric view (b) side view.
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(a)

(b)
Figure D-15. Outflow pattern and velocity at cannula outlet in 30 mm tissue with 20° x 13 mm
Lg. cannula geometry (a) isometric view (b) side view.
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(a)

(b)
Figure D-16. Outflow pattern and velocity at cannula outlet in 12 mm tissue with 20° x 17 mm
Lg. cannula geometry (a) isometric view (b) side view.
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(a)

(b)
Figure D-17. Outflow pattern and velocity at cannula outlet in 18 mm tissue with 20° x 17 mm
Lg. cannula geometry (a) isometric view (b) side view.
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(a)

(b)
Figure D-18. Outflow pattern and velocity at cannula outlet in 24 mm tissue with 20° x 17 mm
Lg. cannula geometry (a) isometric view (b) side view.
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(a)

(b)
Figure D-19. Outflow pattern and velocity at cannula outlet in 30 mm tissue with 20° x 17 mm
Lg. cannula geometry (a) isometric view (b) side view.
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Appendix E: Chapter 8 Additional Figures

Figure E-1. 12 mm tissue thickness CFD pressure gradient with no insulin delivery.

Figure E-2. 18 mm tissue thickness CFD pressure gradient with no insulin delivery.

Figure E-3. 24 mm tissue thickness CFD pressure gradient with no insulin delivery.
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Figure E-4. 30 mm tissue thickness CFD pressure gradient with no insulin delivery.

Figure E-5. 18 mm tissue thickness CFD pressure gradient with 90° cannula.
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Figure E-6. 24 mm tissue thickness CFD pressure gradient with 90° cannula.

Figure E-7. 30 mm tissue thickness CFD pressure gradient with 90° cannula.
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Figure E-8. 18 mm tissue thickness CFD pressure gradient with 45° cannula.

Figure E-9. 24 mm tissue thickness CFD pressure gradient with 45° cannula.
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Figure E-10. 30 mm tissue thickness CFD pressure gradient with 45° cannula.

Figure E-11. 18 mm tissue thickness CFD pressure gradient with 30° cannula.
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Figure E-12. 24 mm tissue thickness CFD pressure gradient with 30° cannula.

Figure E-13. 30 mm tissue thickness CFD pressure gradient with 30° cannula.
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Figure E-14. 18 mm tissue thickness CFD pressure gradient with 20° 13 mm long cannula.

Figure E-15. 24 mm tissue thickness CFD pressure gradient with 20° 13 mm long cannula.
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Figure E-16. 30 mm tissue thickness CFD pressure gradient with 20° 13 mm long cannula.

Figure E-17. 18 mm tissue thickness CFD pressure gradient with 20° 13 mm long cannula.

Figure E-18. 24 mm tissue thickness CFD pressure gradient with 20° 13 mm long cannula.
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Figure E-19. 30 mm tissue thickness CFD pressure gradient with 20° 13 mm long cannula.

Figure E-20. 6 mm tissue thickness CFD pressure gradient of insulin depot at cannula tip with
90° cannula.
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Figure E-21. 12 mm tissue thickness CFD pressure gradient of insulin depot at cannula tip with
90° cannula.

Figure E-22. 18 mm tissue thickness CFD pressure gradient of insulin depot at cannula tip with
90° cannula.
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Figure E-23. 24 mm tissue thickness CFD pressure gradient of insulin depot at cannula tip with
90° cannula.

Figure E-24. 30 mm tissue thickness CFD pressure gradient of insulin depot at cannula tip with
90° cannula.
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Figure E-25. 6 mm tissue thickness CFD pressure gradient of insulin depot at cannula tip with
45° cannula.

Figure E-26. 12 mm tissue thickness CFD pressure gradient of insulin depot at cannula tip with
45° cannula.
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Figure E-27. 18 mm tissue thickness CFD pressure gradient of insulin depot at cannula tip with
45° cannula.

Figure E-28. 24 mm tissue thickness CFD pressure gradient of insulin depot at cannula tip with
45° cannula.
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Figure E-29. 30 mm tissue thickness CFD pressure gradient of insulin depot at cannula tip with
45° cannula.

Figure E-30. 6 mm tissue thickness CFD pressure gradient of insulin depot at cannula tip with
30° cannula.
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Figure E-31. 12 mm tissue thickness CFD pressure gradient of insulin depot at cannula tip with
30° cannula.

Figure E-32. 18 mm tissue thickness CFD pressure gradient of insulin depot at cannula tip with
30° cannula.
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Figure E-33. 24 mm tissue thickness CFD pressure gradient of insulin depot at cannula tip with
30° cannula.

Figure E-34. 30 mm tissue thickness CFD pressure gradient of insulin depot at cannula tip with
30° cannula.

188

Figure E-35. 6 mm tissue thickness CFD pressure gradient of insulin depot at cannula tip with
20° x 13 mm long cannula.

Figure E-36. 12 mm tissue thickness CFD pressure gradient of insulin depot at cannula tip with
20° x 13 mm long cannula.
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Figure E-37. 18 mm tissue thickness CFD pressure gradient of insulin depot at cannula tip with
20° x 13 mm long cannula.

Figure E-38. 24 mm tissue thickness CFD pressure gradient of insulin depot at cannula tip with
20° x 13 mm long cannula.
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Figure E-39. 30 mm tissue thickness CFD pressure gradient of insulin depot at cannula tip with
20° x 13 mm long cannula.

Figure E-40. 6 mm tissue thickness CFD pressure gradient of insulin depot at cannula tip with
20° x 17 mm long cannula.
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Figure E-41. 12 mm tissue thickness CFD pressure gradient of insulin depot at cannula tip with
20° x 17 mm long cannula.

Figure E-42. 18 mm tissue thickness CFD pressure gradient of insulin depot at cannula tip with
20° x 17 mm long cannula.
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Figure E-43. 24 mm tissue thickness CFD pressure gradient of insulin depot at cannula tip with
20° x 17 mm long cannula.

Figure E-44. 30 mm tissue thickness CFD pressure gradient of insulin depot at cannula tip with
20° x 17 mm long cannula.
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Appendix F: Chapter 9 Additional Figures

(a)

(b)
Figure F-1. Average drug dispersion from cannula for 18 mm tissue and 90° cannula (a) top view
(b) side view.
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(a)

(b)
Figure F-2. Average drug dispersion from cannula for 24 mm tissue and 90° cannula (a) top view
(b) side view.
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(a)

(b)
Figure F-3. Average drug dispersion from cannula for 30 mm tissue and 90° cannula (a) top view
(b) side view.

196

(a)

(b)
Figure F-4. Average drug dispersion from cannula for 18 mm tissue and 45° cannula (a) top view
(b) side view.
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(a)

(b)
Figure F-5. Average drug dispersion from cannula for 24 mm tissue and 45° cannula (a) top view
(b) side view.
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(a)

(b)
Figure F-6. Average drug dispersion from cannula for 30 mm tissue and 45° cannula (a) top view
(b) side view.
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(a)

(b)
Figure F-7. Average drug dispersion from cannula for 18 mm tissue and 30° cannula (a) top view
(b) side view.
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(a)

(b)
Figure F-8. Average drug dispersion from cannula for 24 mm tissue and 30° cannula (a) top view
(b) side view.
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(a)

(b)
Figure F-9. Average drug dispersion from cannula for 30 mm tissue and 30° cannula (a) top view
(b) side view.
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(a)

(b)
Figure F-10. Average drug dispersion from cannula for 18 mm tissue and 20° x 13 mm Lg.
cannula (a) top view (b) side view.
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(a)

(b)
Figure F-11. Average drug dispersion from cannula for 24 mm tissue and 20° x13 mm Lg.
cannula (a) top view (b) side view.
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(a)

(b)
Figure F-12. Average drug dispersion from cannula for 30 mm tissue and 20° x 13 mm Lg.
cannula (a) top view (b) side view.
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(a)

(b)
Figure F-13. Average drug dispersion from cannula for 18 mm tissue and 20° x 17 mm Lg.
cannula (a) top view (b) side view.
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(a)

(b)
Figure F-14. Average drug dispersion from cannula for 24 mm tissue and 20° x 17 mm Lg.
cannula (a) top view (b) side view.
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(a)

(b)
Figure F-15. Average drug dispersion from cannula for 30 mm tissue and 20° x 17 mm Lg.
cannula (a) top view (b) side view.
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